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Safety evidence for use of pharmaceutical drugs in children, including treatments for 
serious conditions such as chronic inflammatory diseases, is generally scarce. Off-label 
use is common and clinicians need to rely on evidence from adults when prescribing to 
children. This is concerning because safety profiles might differ; the metabolism, 
distribution and absorption of drugs vary between children and adults.  
The overall aim of this thesis was to develop new, relevant, and pediatric-specific drug 
safety evidence for treatments of chronic inflammatory disease; both addressing 
specific safety concerns and screening for signals of previously unknown adverse 
events. Sub-aims were to evaluate the feasibility of these types of safety studies in the 
Scandinavian setting and to examine the differences between alternative 
pharmacoepidemiologic study designs. We conducted analyses based on data from 
Swedish and Danish national registers covering a source population of 5.3 million 
children; including 21,000 patients with confirmed chronic inflammatory disease.  
In the first study, the aim was to investigate if there is an association between the use of 
azathioprine and the risk of acute pancreatitis in Swedish and Danish patients with 
pediatric inflammatory bowel disease (IBD). We found that azathioprine was associated 
with a 6-fold increased risk of acute pancreatitis during the first 90 days following 
treatment initiation, compared to no use, based on a sample of 8725 patients (n=3574 
azathioprine users).  
In the second study, we investigated if there is an association between use of tumor 
necrosis factor-alpha (TNF-α) inhibitors and the risk of serious infection in patients 
with pediatric IBD in Denmark. We found no significant association between current 
use of TNF-α inhibitors and the risk of serious infection, based on 2817 patients (n=618 
TNF-α inhibitor users), in comparison with no use. 
The aim of the third study was to perform data mining to detect previously unknown 
adverse events of TNF-α inhibitors in children with IBD or juvenile idiopathic arthritis 
(JIA) in Denmark. We used tree-based scan statistics on 1284 incident diagnoses 
identified during follow-up and found two significant signals, dermatologic 
complications and psychiatric adjustment disorders. Neither of these signals were 
considered relevant for further investigation. 
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In the fourth study, we systematically described and compared various 
pharmacoepidemiologic designs, in particular alternatives to the active comparator new 
user design. We used target trial emulation as a common framework and drew two 
conclusions. That eligibility is the key design element that differentiates the designs and 
that many factors influence the choice of an ideal comparator, including indication, 
available comparator drugs, treatment patterns, potential effect modification, and 
sample size. 
In the fifth and final study, we investigated if there is an association between use of 
TNF-α inhibitors and the risk of serious infection in Danish patients with JIA. Based on 
4493 JIA patients (n=578 TNF-α inhibitor users), we found that current use of TNF-α 
inhibitors was associated with a two-fold increased risk of serious infection, compared 
to methotrexate. 
In summary, we provided data on three current drug safety concerns in children with 
chronic inflammatory disease; we showed that Scandinavian health registers are 
suitable for both targeted and adverse-event signal detection studies; and finally, we 
provided guidance on the factors that need to be considered when selecting 
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“The committee believes that it is unethical to adhere to a system which forces physicians to use 
therapeutic agents in an uncontrolled experimental situation virtually every time they 
prescribe for children. Furthermore, it is not only ethical but also imperative that new drugs to 
be used in children be studied in children under controlled circumstances so the benefits of 
therapeutic advances will become available to all who may need them” 
–American Academy of Pediatrics1 
 
The formal testing of pharmaceutical drugs before they are used in clinical practice was 
established during the previous century. Historic disasters have prompted the 
development of new legislation, in particular the death of more than 100 people in 1937 
after using a sulfanilamide elixir and the widespread use of thalidomide in the late 
1950s that caused deformities in more than 5000 babies.2 The modern approval of 
novel drugs is a highly regulated process where efficacy and safety are assessed based 
on clinical trials in increasingly larger cohorts. Despite this progress, some patient 
groups are still underrepresented in or even excluded from the testing of new therapies. 
One such group is children.3,4  
There is generally less drug safety information in children than in adults; the proportion 
of drugs used in children without proper labeling has been estimated at 54%.5 The 
participation of children in clinical trials is very low due to ethical, practical and 
financial reasons.6,7 As a consequence, clinicians treating children need to make 
decisions based on data extrapolated from adults and clinical judgement rather than 
specific safety evidence for children. This can lead to suboptimal treatment because 
children are different from adults with respects to their physiology, organ development, 
and their drug absorption, distribution and metabolization.8 Hence the safety profile of 
a drug can be different in pediatric patients in comparison with adults. 
Off-label pharmacotherapy in children is high.9,10 Since market forces alone have not 
stimulated the development of pediatric safety evidence several legal and regulatory 
efforts have been made to increase the inclusion of children in randomized controlled 
trials (RCT), both in the United States and Europe.11 The first efforts to stimulate 





had positive long-term effects and more children have been included in trials, there is 
still a general lack of safety evidence for pediatric patients. The legal incentives have 
also been criticized for incurring high societal cost and not prioritizing pediatric-specific 
studies based on clinical needs.4,12 Furthermore, results from many clinical trials of 
children are not published. The proportion of pediatric phase III RCTs that are not 
published is estimated at 30% and one factor influencing nonpublication is failure to 
enroll enough patients.13 
Given the obstacles in conducting RCTs on children and the limited output, 
observational studies play a critical role in the development of safety evidence for 
pediatric patients.14-16 There are several general advantages of observational safety 
studies, among them the possibility to analyze larger samples with longer follow-up, 
which allows for higher precision and the study of rare adverse events. This is 
particularly important when studying children as they have lower prevalence of disease 
and drug use; resulting commonly in sample size issues in RCTs.13,17 Studying drug 
safety from routine clinical care also increases relevance and generalizability of the 
results. Despite the advantages of observational studies, and that they in many cases 
represent the only source of pediatric-specific evidence, there is still a shortage of this 
type of research.16 
In this thesis project we addressed current drug safety concerns in children with focus 
on chronic inflammatory diseases. The overall aim was to develop new, relevant, and 
pediatric-specific drug safety evidence for treatments in pediatric inflammatory bowel 
disease (IBD) and juvenile idiopathic arthritis (JIA); both addressing specific safety 
concerns and screening for new signals of adverse events. Sub-aims were to evaluate 
the feasibility of these types of safety studies in the Scandinavian health care register 
setting and to investigate the pros and cons of common pharmacoepidemiologic study 
designs. The specific aims of the papers were: 
- Study I: To investigate if there is an association between use of azathioprine and 
the risk of acute pancreatitis in Swedish and Danish children with IBD. 
- Study II: To investigate if there is an association between use of tumor necrosis 
factor-alpha (TNF-α) inhibitors and the risk of serious infection in Danish 
children with IBD. 
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- Study III: To screen for signals of previously unknown adverse events of TNF-α 
inhibitors in Danish pediatric patients with IBD or JIA by applying data mining 
methods to nationwide health care registers. 
- Study IV: To systematically describe and compare alternative 
pharmacoepidemiologic designs, and to present a case example where the 
designs are applied in a real-world drug safety assessment to illustrate the 
differences. 
- Study V: To investigate if there is an association between the use of TNF-α 
inhibitors and the risk of serious infection in patients with JIA. 
We conducted analyses based on linked data from nationwide health care and 
administrative registers in Sweden and Denmark. We used a complete binational cohort 
of 21,000 pediatric IBD and JIA patients with an average follow-up of 4.4 years and 
individual data on demographics, diagnoses and procedures in specialist care, 
pharmaceutical drug use, and socioeconomic status of patients’ parents. 
In the next section of this thesis summary (section 2), we review the safety concerns in 
pediatric IBD and JIA that were investigated. In section 3, data sources, study designs, 
and statistical methods are described. Section 4 contains summaries of the background 
and key results of papers I-V. We discuss the clinical implications, methodological and 
ethical considerations, and a few points on the future of pediatric 
pharmacoepidemiology in section 5. Section 6 contains conclusions. In sections 7 and 8, 
popular science summaries are provided in English and Swedish, respectively. Finally, 
acknowledgments can be found in section 9 and references in section 10. At the end, 








In this section we describe the treatment patterns in pediatric IBD and JIA, and review 
the current literature on the safety concerns that were investigated in this thesis. 
 
2.1 TREATMENT IN PEDIATRIC IBD AND JIA 
IBD and JIA represent some of the most common serious health conditions in pediatric 
patients. IBD is characterized by chronic inflammation of the gastrointestinal tract and 
typically includes ulcerative colitis (UC), Crohn’s disease (CD), and unclassified IBD. The 
incidence rate of pediatric IBD in Sweden has been estimated at 18.5 per 100,000 
person-years,18 but there is large geographic variation and incidence rates have 
increased in western countries in recent years.19,20  
In UC, 5-aminosalicylic acid (5-ASA) is the recommended induction therapy for mild and 
moderate cases.21 This treatment is also used as first-line maintenance therapy, 
although it is often replaced by azathioprine, which is more efficacious.22 Azathioprine 
is also one of the recommended maintenance treatments in CD, with pediatric-specific 
efficacy evidence.23-25 5-ASA is also used in CD, but is controversial due to lack of 
evidence and is only recommended for use in very mild disease.25 
JIA is a heterogeneous group of autoimmune diseases characterized by arthritis of 
unknown etiology with onset before the age of 16 years that persists for at least six 
weeks.26 There are seven distinct types of JIA: systemic arthritis, oligoarthritis, 
polyarthritis (rheumatoid factor negative or positive), psoriatic arthritis, enthesitis-
related arthritis, and undifferentiated arthritis.26 Criteria for each diagnosis include the 
number of joints affected, symptoms and laboratory tests. A meta-analysis estimated 
the incidence of JIA at 8.2 per 100,000 person-years, standardized to the European 
population.27  
In JIA, the treatment strategies vary depending on disease type, but general initial 
therapy includes nonsteroidal anti-inflammatory drugs (NSAID), which are used to 
manage symptoms and pain. In active disease, local glucocorticoid injections have been 
recommended regardless of concurrent therapy and across JIA types.28 The most widely 
used disease-modifying drug in JIA is methotrexate (MTX),29,30 which can be 
administered both orally and subcutaneously. It has proven efficacy since the early 
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1990s and is recommended in all subtypes of JIA, although its role in enthesitis-related 
arthritis is unclear.31 It is generally recommended to continue MTX, at least initially, 
following start of treatment with TNF-α inhibitors.28  
Biologic treatment, in particular TNF-α inhibitors, has revolutionized the treatment of 
inflammatory diseases and has become increasingly common in the treatment of both 
children and adults. TNF-α inhibitors have proven efficacy as induction and 
maintenance therapies in pediatric IBD. In patients with CD and UC, 88% and 73% 
respond to TNF-α inhibitor treatment while 59% and 29% are in remission after one 
year, respectively.32-34 In JIA, efficacy has been established in multiple clinical trials.35,36  
The recommendations are reflected by the treatment patterns observed in clinical 
practice. In Danish pediatric patients with disease onset 2007-2016, 5-ASA was more 
prevalent in UC than in CD patients (Figure 1). The proportions of patients who used 5-
ASA in the first five years were 78% and 22% in UC and CD, respectively. Most UC 
patients, 72%, started 5-ASA treatment in the first year following disease onset. In 
contrast, thiopurines were more common in CD; where 69% in comparison with 48% in 
UC used the drug in the first five years. In the first year, 58% of CD patients started 
thiopurines. Among JIA patients, NSAIDs were used by 83% in the first five years, with 
71% using them in the first year. MTX was used by 21% in the first five years. Use of 
TNF-α inhibitors gradually increased in prevalence over the 5 years following disease 
onset in all diseases. Their use was most prevalent in CD patients, where 47% used 
TNF-α inhibitors in the first 5 years, while the proportions in UC and JIA were 27% and 
20%, respectively. 
There is a general lack of pediatric-specific safety evidence for the most common 
treatments in pediatric IBD and JIA. Below we summarize the current literature on the 
safety concerns that were investigated in this project: the potential association between 
use of thiopurines and the risk of acute pancreatitis in pediatric IBD; and between use of 







Figure 1. Cumulative drug use in Danish UC, CD and JIA patients during the first five years 
































































































2.2 THIOPURINES AND THE RISK OF ACUTE PANCREATITIS IN PEDIATRIC 
IBD  
Several RCTs have indicated that acute pancreatitis is an adverse effect of thiopurines In 
adult IBD, including azathioprine and 6-mercaptopurine, and that the risk is higher 
among CD patients compared to UC patients. A Cochrane review of RCTs (11 trials; total 
N=881) on use of azathioprine or 6-mercaptopurine in adult CD concluded that 
pancreatitis was among the most common adverse events that led to withdrawal of 
treatment,24 although the relative risk of pancreatitis was not estimated. Some of the 
included RCTs showed large risk differences between azathioprine and comparators. In 
one RCT of 142 adult CD patients randomized to either early azathioprine treatment or 
conventional therapy, n=7/71 (10%) in the azathioprine group had pancreatitis events 
versus n=2/71 (3%) in the comparator group (no p-value presented).37 In another trial, 
adult CD patients were randomized to either azathioprine or placebo and n=7/68 
(10%) and n=0/63 (0%) (p-value 0.01) developed pancreatitis, respectively.38 
A Cochrane review on adult UC and use of azathioprine and 6-mercaptopurine (6 trials; 
total n=279) showed a lower absolute risk of pancreatitis (2%) in patients treated with 
azathioprine compared with the studies in CD.39 There was no statistically significant 
difference between treated and controls in the meta-analysis, although the analysis was 
based on very small numbers (n=3/141 [2%] versus n=0/138 [0%], risk ratio [RR] 4.13, 
95% confidence interval [CI] 0.48 to 35.48).  
Among observational studies in adult IBD, a recent German study prospectively 
followed 510 patients with IBD who initiated treatment with azathioprine.40 There was 
a larger proportion of CD patients (8.6%) compared to UC patients (3.2%) who 
developed pancreatitis after azathioprine initiation. Azathioprine-associated 
pancreatitis occurred after a median of 21 days and less than half of the cases resulted 
in hospitalization (43%). 
In pediatric IBD, only one RCT has been conducted on the use of thiopurines (CD; 
N=55).23 In the trial, the combination of 6-mercaptopurine and prednisone was 
compared with placebo and prednisone and no patients developed symptoms of acute 
pancreatitis. A few observational studies on thiopurine use in pediatric IBD have been 
conducted but none of them have included comparator groups. A prospective register 
study from the United States on pediatric UC (N=197) showed that 2% (n=4) of the 





pancreatitis during follow-up.41 Other small case series have reported absolute risks of 
pancreatitis in the range of 1.1-6.4% among pediatric IBD patients initiating thiopurine 
treatment: n=1/88 (1.1%) (CD)42, n=2/79 (2.5%) (UC/CD)43, and n=6/93 (6.4%) (CD)44. 
In summary, safety evidence on the use of thiopurines that is specific to pediatric IBD 
patients is scarce and inconclusive. None of the studies in pediatric IBD described above 
have been specifically designed or powered to investigate if thiopurine use is associated 
with the risk of acute pancreatitis. Despite the general lack of safety evidence, 
thiopurine is commonly prescribed in pediatric IBD. In study I, we investigated the 
potential association between use of azathioprine, the most widely used thiopurine in 
Scandinavia, and the risk of acute pancreatitis in a nationwide Swedish and Danish 
pediatric IBD cohort.  
 
2.3 TNF-ALPHA INHIBITORS AND THE RISK OF SERIOUS INFECTIONS IN 
PEDIATRIC IBD AND JIA 
TNF-α inhibitors are generally considered safe but whether they increase the risk of 
infection in pediatric patients is controversial. In adults, a large Cochrane review from 
2011 (160 RCTs) showed an increased risk of serious infections (defined in most 
studies as infections requiring hospitalization) in patients initiating biologics treatment 
as compared with controls (odds ratio [OR] 1.39, 95% CI 1.18 to 1.64).45 The increased 
risk was similar when restricting the analysis to TNF-α inhibitors (116 RCTs; OR 1.41, 
95% CI 1.13 to 1.75). RCTs on rheumatoid arthritis (RA) patients dominated the 
included studies (62 RCTs; OR 1.55, 95% CI 1.23 to 1.95). When the analysis was 
restricted to IBD patients (12 RCTs) there was no significant association, though the CI 
was wide (OR 1.28, 95% CI 0.67 to 2.44). In another study, a network meta-analysis of 
RCTs in RA, the results showed a dose-dependent increased risk of serious infections 
associated with the use of biologics: significantly higher risk in patients with high dose 
(OR 1.90, 95% credible interval 1.50 to 2.39) and standard dose (OR 1.31, 95% credible 
interval 1.09 to 1.58), but not in low-dose patients (OR 0.93, 95% credible interval 0.65 
to 1.33).46 A more recent meta-analysis of RCTs on TNF-α inhibitor use in adult IBD 
from 2016 (33 RCTs; total n=10,015) found no association between TNF-α inhibitors 
and increased risk of serious infection or death (OR 0.90, 95% CI 0.69 to 1.17). 
However, there was an increased risk of any infection, which also included infections in 
outpatient care (OR 1.21, 95% CI 1.10 to 1.33).47  
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The observational evidence in adult IBD and RA indicates an increased risk of serious 
infection. A large American study in RA based on claims data (N=31,801) found a 
significantly increased risk of serious infection associated with initiation of etanercept 
(hazard ratio [HR] 1.24, 95% CI 1.07 to 1.45) and infliximab (HR 1.39, 95% CI 1.21 to 
1.60), as compared with abatacept.48 Multiple observational studies in IBD have shown 
similar associations. A prospective study from 2012 (n=3420 exposed), a large 
retrospective study from 2018 (n=26,255 exposed), and a study of young adults (age 
18-29; n=3574 exposed) showed significant associations between TNF-α inhibitor use 
and risk of serious infection in adult IBD (HRs: 1.43, 95% CI 1.11 to 1.8449; 1.71, 95% CI 
1.56–1.8850; 1.49, 95% CI 1.12 to 1.9851, respectively). A Swedish observational study in 
RA (n=4167 exposed) found a statistically significant association between use of TNF-α 
inhibitors and risk of serious infection during the first year of follow-up (HR 1.43, 95% 
CI 1.18 to 1.73) but not in year two (HR 1.15, 95% CI 0.88 to 1.51) or year three (HR 
0.82, 95% CI 0.62 to 1.08).52 Similarly, a Danish study in IBD patients (n=1543 exposed) 
found an increased risk of serious infection in TNF-α inhibitor users shortly following 
initiation (first 3 months: HR 1.63; 95% CI 1.01 to 2.63) and no significant association 
during the entire follow-up of 1 year (HR 1.27, 95% CI 0.92 to 1.75).53 Finally, another 
large American study based on claims data found no significant associations between 
TNF-α inhibitor use and risk of serious infection in RA patients (N=10,484; HR 1.05, 
95% CI 0.91 to 1.21) or IBD patients (N=2323; HR 1.10, 95% CI 0.83 to 1.46), as 
compared with non-biologic treatment.54  
In pediatric patients, two prospective studies in JIA have investigated the association 
between use of TNF-α inhibitors and risk of serious infection. The first study found a 
significant association with use of etanercept (n=1414; RR 2.12, 95% CI 1.08 to 4.17) 
and not with adalimumab (n=320; RR 0.88, 95% CI 0.18 to 4.28).55 The second study 
had lower power and found no significant association with etanercept (n=852), HR 1.36 
(95% CI 0.60 to 3.07).56 However, both studies reported higher ratios when 
investigating the risk of infection based on wider outcome definitions. A recent meta-
analysis in JIA (n=1434 exposed) found no statistically significant association between 
TNF-α inhibitor use and risk of infections overall (OR 1.13, 95% CI 0.76 to 1.69).57 The 
review did not investigate the risk of serious infections.  
In pediatric IBD, a cohort study on TNF-α inhibitor use in young adults is the only study 





analysis showed no significant association between TNF-α inhibitor use and risk of 
serious infections in children, HR 1.12 (95% CI 0.75 to 1.68). A meta-analysis from 2014 
in pediatric IBD also showed no increased incidence rate of serious infections in TNF-α 
inhibitor users (standardized incidence ratio 1.06, 95% CI 0.83 to 1.36).58 However, the 
results carry limited relevance due to inclusion of small case series, use of an unsuitable 
comparator group and lack of confounding control. 
The safety evidence of TNF-α inhibitor in pediatric IBD and JIA is limited and concerns 
have been raised regarding the risk of serious infections. More information is needed to 
support clinical practice and decisions on optimal treatment strategy. We investigated if 
there is an association between use of TNF-α inhibitors and the risk of serious infection 







3 MATERIALS AND METHODS 
In this section, we summarize the data sources and methods used in studies I-V. The 
section includes definition of source populations, study populations, study designs and 
statistical methods. For additional information, see the individual papers and the 
supplementary material. The methods are discussed in more detail in section 5.2. 
 
3.1 DATA SOURCES 
All analyses in this project were based on data from Swedish and Danish health care and 
administrative registers with nationwide coverage. The general source population for 
the pediatric analyses (all studies except IV, discussed below) was children (age <18 
years) who resided in Sweden (2005 to 2016) or Denmark (2000 to 2016). The 
population amounted to approximately 5.3 million individuals and was identified 
through national population registers (The Total Population Register in Sweden and 
The Danish Civil Registration System).59-61 From the source population we extracted 
data on all patients with any diagnosis of chronic inflammatory disease during the 
general study periods or three years before. We identified 8700 unique patients with 
IBD diagnosis and 12,600 patients with JIA diagnosis. Patient-level, longitudinal data 
from multiple registers was linked via personal identification numbers and all data was 
anonymized before analysis.62 An overview of the data sources can be found in Figure 2. 
In study I, we utilized both Swedish and Danish data that were analyzed separately. 
Aggregated results were pooled for the main analysis. In studies II, III and V, the 
analysis was performed in Denmark where the coverage of hospital administered TNF-
α inhibitors in the national patient register is close to complete.63,64 Treatment with 
biologics in Denmark is administered in specialist care and does not incur any cost for 
the patient.  
From the population registers and multi-generation registers we extracted data on 
demographics (date of birth, sex, migration, date of death) and linked individuals to 
their parents.59-61,65 As the study population was pediatric education level and income of 
patients’ parents or guardians (extracted from Longitudinal Integration Database for 
Health Insurance and Labour Market Studies [LISA] in Sweden and socioeconomic 
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The national patient registers in Denmark and Sweden, which include all physician-
assigned diagnoses and performed procedures in secondary care (outpatient visits and 
inpatient admissions), were used to identify the cohort of patients with chronic 
inflammatory disease and for identifying comorbidities, disease history and 
outcomes.35,66,67 The national drug registers, which cover all dispensings of prescription 
drugs including prescriptions originating from primary care, were used to identify 
exposure, co-medication and treatment history.68-70  
A strength of the Danish and Swedish data sources is the nationwide coverage of 
diagnoses, procedures and drug use from routine clinical care. The general access to 
health care and subsidized use of prescription drugs in both countries enable 
population-wide coverage. The sample size and length of follow-up are comparably 
large for a pediatric cohort. The data sources also have limitations. The Swedish patient 
register does not have complete coverage of hospital administered drugs, while 
administration of biologics is captured in the Danish patient register, as described 
above. There is no structured data on dosing, which can hamper estimation of duration 
of prescription fills and complicate exposure definitions that are based on prescribed 
dose. Finally, there is no data on diagnoses from the primary care setting with national 
coverage.  
In study IV, we performed an illustrative case example that was based on a cohort of 
adult type 2 diabetes patients, derived from the data sources described above (only 
Sweden). The source population for the analysis was all patients who had filled a 
prescription of a type 2 diabetes drug (Anatomical Therapeutic Chemical [ATC] A10) 
during the study period (July 2013 to December 2018). We identified 574,999 unique 
patients who were eligible at some time point during the study period. The case 
example was based on a previously published study71 and was chosen based on the 
large sample and well-established safety concern (sodium glucose cotransporter 2 
[SGLT2] inhibitors and the risk of ketoacidosis) to enable clear illustration of the 






3.2 STUDY DESIGN 
3.2.1 Study populations 
All studies used cohort designs; eligible individuals were identified at certain time 
points (index dates) and followed until event or censoring, whichever occurred first. 
Patients with confirmed disease were included in the study cohorts.  
The pediatric IBD cohorts for studies I, II and III were identified based on data from the 
national patient registers. Patients with at least two contacts (inpatient or outpatient) 
with specialist care with a physician assigned IBD diagnosis during or before the study 
periods were included. In study I, the study period was July 2006-2016 in Sweden and 
2000-2016 in Denmark, due to the earlier launch of the drug register in Denmark. The 
study period in study II, which was only based on Danish data, 2007-2016, started a few 
years after drug approval to avoid inclusion of early users. In study III, where we 
screened for signals of new adverse events, the study period started from the approval 
of TNF-α inhibitors in Denmark (2004-2016). 
The Danish JIA cohort, analyzed in studies III and V, was also identified based on the 
national patient register. In study III, at least two JIA diagnoses from specialist care 
were required. In study V, the study period was the same as in study II, 2007-2016, and 
at least two JIA diagnoses in specialist care were required, where the first diagnosis was 
recorded at age 16 or younger. 
In the case example of study IV, we identified type 2 diabetes patients based on drug use 
rather than diagnosis. At least two filled prescriptions of any diabetes drug (ATC A10) 
during the study period (July 2013 to December 2018) were required. Using indication-
specific drugs for cohort definition had the advantage of also capturing patients who 
were diagnosed and treated in the primary care setting. 
 
3.2.2 Exposures and comparators 
Drug use was identified based on filled prescriptions in the Danish National 
Prescription Registry and the Swedish Prescribed Drug Register. Records of Hospital 




In studies I-III, we used no-use episode designs where we identified episodes of new 
use (no previous use during a fixed look-back period) of the study drug and episodes of 
no use of that drug for each individual in the study population.72,73 The study drugs 
were azathioprine in study I and TNF-α inhibitors in studies II and III. All eligible 
follow-up, post confirmed disease, contributed to the episodes. Hence, all time with 
neither current nor recent use of the study drug was divided into mutually exclusive 
no-use episodes, which made up the comparator. Maximum episode length was one 
year in study I, and three years in studies II and III (Figure 3). In this design, one patient 
could contribute to both exposed and no-use episodes. However, because there was no 
overlap between the episodes and patients with a history of the outcome were 
excluded, no individual patient could contribute with multiple events.  
In study V, we used a modified (or generalized) prevalent new user design74 where 
initiators of TNF-α inhibitors were compared with incident and prevalent users of an 
active comparator, MTX. With this design we were able to use an active comparator, 
while not excluding initiators of the study drug, TNF-α inhibitors, who were prevalent 
in the comparator. Further, in relation to the standard prevalent new user design, we 
did not use time-dependent propensity score (PS) matching, which meant that all 
exposed observations were retained in the analysis. To form this analytical cohort, we 
pooled a large set of sequential cohorts identified during the study period.75,76 The study 
period was divided into short intervals and one sequential cohort was identified for 
each interval. Individuals from the source population (described above) who met the 
eligibility criteria during a given interval were included in that sequential cohort.  
In study IV, we sought to demonstrate how different pharmacoepidemiologic designs, 
including no-use episodes and generalized prevalent new user, can be defined based on 
the target trial emulation framework and sequential cohorts. In target trial emulation, 
an observational study is designed by emulating a hypothetical clinical trial, element by 
element. By being explicit about the emulation, the design of the observational study is 
transparent and potential biases can be addressed (more information in section 5.2.2).76 
In the case example of study IV, we reanalyzed a previously published drug safety 
assessment in adults with type 2 diabetes: the association between use of SGLT2 






Figure 3. Examples of 
episodes of new study 
drug use and no-use 
episodes with an as-
treated design and a 
maximum follow-up of 
three years and wash-out 
of two years 
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Example i. Incident disease patient; no study drug use during follow-up and contributed with 7 no-use episodes
Example ii. Incident disease patient; contributed with 1 study drug episode and 4 no-use episodes
Example iii. Prevalent disease patient; contributed with 2 study drug episodes and 5 no-use episodes




No use episodesDrug duration and 
grace period
Drug duration and grace period following last study drug dispensing in sequence
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3.2.3 Eligibility and censoring 
The general exclusion criteria that were applied to all analyses at baseline (based on 
fixed look-back periods) were: previous use of the study drug, history of the outcome 
event (to only study incident events), and residing outside of the country (to make sure 
that covariate status and data related to exclusion were updated and had been collected 
equally between patients). In all studies (except the case example of study IV) patients 
of age ≥18 years at baseline were excluded and patients with no recent hospital contact 
with a diagnosis for the underlying disease (IBD or JIA) were excluded to avoid 
including patients without regular contact with health care or with very mild disease. 
Additionally, in studies II and V, we also excluded patients with history of 
immunodeficiency, previous use of biologics, or diseases that might require 
immunosuppressing treatments (e.g. HIV and cancer) to limit the risk of confounding. 
Due to the non-targeted nature of study III, where we performed data mining for new 
signals of adverse events, the exclusion criteria were less restrictive.  
We used as-treated designs in the main analyses of all studies, i.e. patients were 
followed as long as they adhered to their baseline treatment strategy. In study I, the 
maximum length of follow-up in the main analysis was short (90 days) and azathioprine 
episodes were not censored due to treatment changes, while no-use episodes were 
censored at initiation of azathioprine, if any. In the as-treated analyses of TNF-α 
inhibitor use in studies II, III and V, patients were censored at treatment cessation in the 
TNF-α inhibitor group and initiation of a TNF-α inhibitor in the comparator group, if 
any. The duration of TNF-α inhibitor use was based on the dosing schedule of treatment 
guidelines and a grace period of 60 days in studies II and V, and 90 days in study III. 
Additionally, in study V the duration of subcutaneous TNF-α inhibitors was set to 60 
days to account for potential dispensing of biologics for self-administration. In the case 
example of study IV, we assumed the same durations per prescription fill as in the 
original study.71 Other reasons for censoring were end of study period, maximum 




All analyses were targeted at specific outcome events except study III, where we 





physician-assigned diagnoses in specialist care, derived from the national patient 
registers. The primary outcome in study I was acute pancreatitis, defined as a contact 
with specialist care (inpatient or emergency outpatient) with a diagnosis of acute 
pancreatitis. The primary outcome in studies II and V was serious infection, defined as 
an inpatient hospital admission with a physician-assigned diagnosis for any infection. In 
study IV, the outcome of the case example was diabetic ketoacidosis, defined as any 
contact with specialist care (inpatient or outpatient) with a diagnosis of diabetic 
ketoacidosis. The date of health care contact or admission was the date of event. 
 
 
3.3 STATISTICAL ANALYSES 
3.3.1 Confounding adjustment 
We used propensity score (PS) methods to adjust for confounding in all studies. The PS, 
which is the conditional probability of treatment, was estimated with logistic 
regression. In the PS models we included general socio-demographic factors, such as 
age, sex, socioeconomic status (from parents in the pediatric studies), and measures of 
health care use. Additionally, we adjusted for disease history, treatment history, and 
factors related to the severity of the underlying disease, that were potential 
confounders. Covariate balance at baseline following adjustment was assessed using 
standardized mean differences, where a difference below 0.1 was considered consistent 
with well-balanced groups. 
In studies I and III, we used 1:1 PS matching with a greedy nearest neighbor algorithm. 
The caliper (maximum difference in PS between exposed and comparator) was 20% of 
the pooled standard deviation of the logit PS in study I,77 and 200% of the same in study 
III to ensure that all exposed episodes were included in the matched cohort. 
Additionally, in study III, we required an exact match on the underlying disease of JIA, 
CD or UC. 
In studies II, IV and V, we used different types of PS weighting to adjust for confounding. 
In studies II and IV, we used standardized mortality ratio (SMR) weights and fine-
stratification weights, respectively, to estimate the average treatment effect in the 
treated (ATT) (Table 1). Only comparator observations were weighted to achieve a 
similar distribution of covariates as in the exposed. In study V, we used stabilized 
inverse probability of treatment (IPT) weighting, to estimate the average treatment 
26 
 
effect (ATE) or the marginal effect, in the TNF-α inhibitor initiators and MTX users. In all 
weighted analyses, observations with PS outside the common range were excluded 
from the analysis.  
In all studies, except the case example of study IV, we performed a priori defined 
sensitivity analyses to investigate the robustness of the main results, and subgroup 
analyses to examine effect modification between patient groups. 
 
Table 1. Propensity score weighting methods 
Weighting method Formula Estimand Application 
Standardized mortality 
ratio (SMR) 𝑤𝑖 = {
1,                   𝑖𝑓 𝐴𝑖 = 1
𝑒𝑖
1 − 𝑒𝑖
, 𝑖𝑓 𝐴𝑖 = 0
 
ATT Study II 
Fine-stratification 
𝑤𝑖 = {
1,                       𝑖𝑓 𝐴𝑖 = 1
𝑁𝐴=1;𝑗 𝑁𝐴=1⁄
𝑁𝐴=0;𝑗 𝑁𝐴=0⁄
, 𝑖𝑓 𝐴𝑖 = 0
 
ATT Study IV 
Stabilized inverse-







     𝑒𝑖    
,        𝑖𝑓 𝐴𝑖 = 1
1 − 𝑒
1 − 𝑒𝑖
, 𝑖𝑓 𝐴𝑖 = 0
 
ATE Study V 
Note: 𝑒𝑖 PS in observation 𝑖; 𝑒 marginal PS; 𝑤𝑖 PS weight in observation 𝑖; 𝐴𝑖 treatment in observation 
𝑖 (1 exposed; 0 comparator); 𝑁𝐴 total number of observations with treatment A; 𝑁𝐴;𝑗 number of 
observations with treatment A in PS stratum 𝑗. 
 
3.3.2 Informative censoring adjustment 
We performed as-treated analyses in all studies and patients were censored at deviation 
from the baseline treatment. To adjust for potential informative censoring, i.e. 
differential censoring in relation to the prevalence of risk factors for the outcome, we 
used stabilized inverse probability of censoring (IPC) weighting in studies IV and V 
(Formula 1).78 Weights were calculated for a certain patient and time interval of follow-
up as the inverse of the conditional (on baseline treatment and confounders) 






𝑃(𝐶𝑖,𝑡 = 0|𝐶𝑖,1 = 0,… , 𝐶𝑖,𝑡−1 = 0, 𝐴𝑖)





[Formula 1] IPC weights. 𝑤𝑖,𝑡 stabilized censoring weight for observation 𝑖 at time 𝑡; 𝐶𝑖,𝑡 
censoring status for observation 𝑖 at time 𝑡 (1 censored; 0 not censored); 𝐴𝑖  baseline 
treatment for observation 𝑖; 𝑋𝑖,𝑡 vector of baseline and time updated confounders for 
observation 𝑖 at time 𝑡. 
 
Weights were stabilized by inserting the probability of not being censored conditioned 
on baseline treatment in the numerator. The conditional probability of censoring was 
estimated with logistic regression. Final weights used in the analysis were calculated as 
the product of baseline IPT weights and IPC weights until the time interval analyzed. 
The weights were truncated at the 1st and 99th percentiles to avoid adjusting for 
extreme weights. In studies I-III, we performed naïve analyses with no adjustment for 
potential informative censoring.  
 
3.3.3 Effect estimation 
In study I, we used Poisson regression with offset for patient-time to be able to pool 
aggregate results in subgroups with zero events from the country analyses. With 
Poisson regression we estimated the incidence rate ratios (IRR) of the outcome 
associated with exposure. In study II, we used Cox proportional hazards regression to 
estimate HRs. Robust sandwich estimators were used to account for repeated 
observations in the weighted pseudo population. We assessed the proportional hazards 
assumption by testing if an interaction term between exposure and time was significant. 
In studies IV and V, we estimated the rate ratio of the outcome associated with exposure 
in weighted or matched pooled logistic regression models, where all sequential cohorts 
and follow-up intervals were included.79 The only covariates in the outcome models 
were baseline exposure and time interval (including polynomials) and we accounted for 
repeated and dependent outcome events within individuals. IRRs and HRs with 95% CIs 
not including 1.0 were regarded as statistically significant. In study I, we additionally 
estimated the absolute rate differences with the formula (IRR-1)*comparator incidence 
rate,73 while we used Poisson regression with an identity link in study II. Crude and 
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adjusted (matched or weighted) cumulative incidence curves were estimated with the 
complement of the Kaplan-Meier function. 
 
3.3.4 Data mining with scan statistics 
In study III, we screened for new signals of adverse events of TNF-α inhibitors in 
children with IBD or JIA in Denmark. We used physician-assigned diagnosis codes from 
specialist care (primary and secondary diagnoses; outpatient and inpatient contacts). 
All diagnoses observed during follow-up, at five levels of the ICD-10 code tree (cuts), 
were considered as potential adverse events, i.e. from disease chapters (e.g. I00-99 
diseases of the circulatory system) to four-position codes (e.g. I47.1 supraventricular 
tachycardia) (Figure 4). Events were collected from the register at the three- and four-
position levels across the entire ICD-10 code system. A limited set of diagnoses were not 
assessed since they were considered not relevant as potential adverse events (e.g. 
congenital malformations). 
Two analyses were performed. In the first, we used PS matched tree-based scan 
statistics to compare episodes of TNF-α inhibitor use with episodes of no use. In the 
second, we performed a self-controlled analysis using tree-temporal scan statistics to 
compare temporal risk windows within the TNF-α inhibitor episodes. We only analyzed 
incident events, defined as a code not preceded by the same code on the three-position 
level. The look-back window in the PS matched analysis was infinite and in the self-
controlled analysis the look-back window was three years in relation to the time of the 
event. 
In the PS matched analysis, we used unconditional Bernoulli tree-based scan 
statistics.80,81 The exposure of each observed event was assumed to follow a Bernoulli 
distribution. The null hypothesis was that events in all cuts were equally probable (due 
to the 1:1 matching) to occur in the TNF-α inhibitor as the no-use episodes, while the 
alternative hypothesis was that the risk of events to occur in the TNF-α inhibitor 





Figure 4. Example of tree-based structure of ICD-10 codes (I00-I99) from Chapter to four-position level. Number of events in cut 𝐺, 𝑐𝐺, is calculated 
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In the self-controlled analysis, we used a tree-temporal scan statistic, conditioned on 
the number of events in each cut and assumed that the events were uniformly 
distributed over follow-up under the null hypothesis. The alternative hypothesis was 
that the risk was higher in at least one combination of cut and investigated risk 
window; the log likelihood ratio (LLR) was estimated for each combination. The 
durations of risk windows were 2 days to 1.5 years (half of the maximum follow-up) 
and no window was shorter than 20% of the follow-up day it ended on (e.g. windows 
that ended on day 50 were 10 days or longer). 
For each cut in the PS matched analysis and for each cut-risk window in the self-
controlled analysis the LLR was calculated. Inference was based on Monte Carlo 
simulation because there is no simple expression for the sample distribution of the 
LLRs. See details on the procedure in the box below. Cuts with p-values below 0.05 were 
considered statistically significant.  
 
3.3.5 Statistical software 
The following software packages and applications were used to perform the statistical 
analyses for studies I-V SAS v9.4 (SAS Institute Inc.), TreeScan v1.4 (www.treescan.org), 
and D3.js (v5.14.0). 
 
3.3.6 Ethical approval 
Studies I, II and IV, conducted based on Swedish register data, were approved by the 
regional ethics committee in Stockholm (Ref 2016/2029-31/1; 2017/715-31). Ethical 
approval was not required for studies performed based on Danish register data; those 
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Scan Statistic 








𝑝(𝑐𝑖 + 𝑛𝑖) 
 
p, proportion of exposed in matching cluster   
(0.5 if 1:1 matching); ci, exposed events in 






ki, total exposed events over follow-up in 
node i; wj, length of risk window j; T, total 
length of follow-up. 
 




        𝑛𝐺 =∑(𝑛𝑖)
𝑖∈𝐺
    
G, cut; cG, exposed events in cut G; nG, 




   𝑘𝐺 =∑(𝑘𝑖)
𝑖∈𝐺
    
G, cut; cG,j, exposed events in cut G and risk 
window j; ci,j, exposed events in node i and 
risk window j; kG, total exposed events over 
follow-up in cut G; ki, total exposed events 
over follow-up in node i. 
 
Hypotheses 
𝐻0:   
𝑐𝐺
𝑐𝐺 + 𝑛𝐺
= 𝑝 𝑓𝑜𝑟 𝑎𝑙𝑙 𝑐𝑢𝑡𝑠 (𝐺) 
 
𝐻1:   
𝑐𝐺
𝑐𝐺 + 𝑛𝐺
> 𝑝 𝑓𝑜𝑟 𝑎𝑡 𝑙𝑒𝑎𝑠𝑡  








 𝑓𝑜𝑟 𝑎𝑙𝑙 𝑐𝑢𝑡 𝑎𝑛𝑑 𝑟𝑖𝑠𝑘  







𝑓𝑜𝑟 𝑎𝑡 𝑙𝑒𝑎𝑠𝑡 𝑜𝑛𝑒 𝑐𝑢𝑡  

































































Monte Carlo hypothesis testing 
Monte Carlo simulations were performed for the PS matched analysis and the self-controlled 
analysis, through the following steps (additional definitions in Table 2): 
1) A series of random replicas of the real datasets (9999 iterations) were generated under 
the null hypothesis: 
a. In the PS matched analysis, the exposed events (ci) and unexposed events (ni) 
in each leaf were replaced by random values drawn from a Bernoulli 
distribution with p=0.5, where the total events (ci+ni) was fixed. If multiple 
events occurred in an episode, the events were randomized together to either 
the TNF-α inhibitor or no-use group.  The number of events in each cut (cG and 
nG) was calculated in the real and simulated datasets. One episode could not 
contribute with more than one event to each cut. 
b. In the self-controlled analysis, the day of event for each exposed event was 
replaced by a random value drawn from a uniform distribution over the 
patient’s total follow-up (events had equal probability of occurring at all days 
during follow-up). The number of events in each cut-risk window (cG,j) was 
calculated in the real and simulated datasets. 
2) The test statistics, T (max LLR), were calculated for each random and real dataset. 
3) The test statistics from the real data (LLR for the most likely cut from each analysis) 
were ranked in relation to their corresponding series of simulated test statistics (1 vs 
9999 values per analysis). The p-value was estimated based on the rank of the 





Where r, rank of observed, real test statistic; S, number of iterations. In addition to the most 
likely cut and cut-risk window, we also estimated p-values for second most likely and so on, 






4 SUMMARY OF PAPERS 
In this section, we summarize the background and key results of studies I-V. More 
detailed descriptions can be found in attached papers and supplementary appendices.  
 
4.1 STUDY I: AZATHIOPRINE AND THE RISK OF ACUTE PANCREATITIS IN 
PEDIATRIC IBD 
4.1.1 Background 
Previous studies in adult IBD have indicated that use of thiopurines increase the risk of 
acute pancreatitis. According to studies, between 3 and 7% of patients experience the 
event in the first few months and risk increases up to 8 times have been observed.40,82-84 
In children the evidence is limited to a few case series and no controlled studies have 
been reported.41-44,85 The aim of study I was to investigate if there is an association 
between use of azathioprine, the most commonly used thiopurine in Scandinavia, and 
the risk of acute pancreatitis in Swedish and Danish children with IBD. 
 
 
Figure 5. Study I: Cumulative incidence of acute pancreatitis in the first 90 days in 
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4.1.2 Key results  
Based on Swedish and Danish nationwide data, we identified 3374 episodes of new 
azathioprine use among children with IBD, which were PS matched with episodes of no 
use. In these pairs, the mean (standard deviation [SD]) age was 14.3 (3.2) years, 55% 
were male, 57% had CD and 43% had UC or unclassified IBD. During the first 90 days of 
follow-up, 40 events of acute pancreatitis occurred among the azathioprine treated 
(incidence rate [IR] 49.1 events per 1000 patient-years) and 6 events occurred in the 
no-use group (IR 8.4 events per 1000 patient-years) (Figure 5). Use of azathioprine was 
significantly associated with an increased risk of acute pancreatitis; the IRR was 5.82 
(95% CI 2.47 to 13.72). The absolute rate difference was 1.0 (95% CI 0.3 to 2.6) events 
per 100 patients during the 90-day risk period. In the secondary risk period, days 91-
365 following azathioprine initiation, there was no significantly increased risk (IRR 
0.99, 95% CI 0.31 to 3.11). The risk of acute pancreatitis appeared to be similar between 
subgroups, although the results were uncertain due to few no-use events. 
 
4.2 STUDY II: TNF-ALPHA INHIBITORS AND THE RISK OF SERIOUS 
INFECTION IN PEDIATRIC IBD 
4.2.1 Background 
Previous observational studies have shown an association between use of TNF-α 
inhibitors and increased risk of serious infection in adult IBD; commonly defining 
serious infections as infections requiring hospitalization. Larger studies from various 
settings, including one prospective study and two retrospective studies, showed 
significant associations, HRs ranging between 1.43 and 1.71.4-6 The only controlled 
study that has presented results for pediatric patients (age <18 years) to our 
knowledge, found a non-significant association between TNF-α inhibitor use and the 
risk of serious infection (HR 1.12, 95% CI 0.75 to 1.68) based on insurance claims data 
from the United States.4 Hence, more data is needed to support the understanding of 
this drug safety concern in children. The aim of study II was to investigate if there is an 
association between use of TNF-α inhibitors and the risk of serious infection in Danish 




4.2.2 Key results  
Based on Danish nationwide data, we identified 618 episodes of new TNF-α inhibitor 
use and 2925 no-use episodes, among children with IBD. In the PS weighted cohort, 
53% were male, mean (SD) age was 15.1 (1.7) years, 70% had CD and 30% had UC or 
unclassified IBD. The most commonly initiated TNF-α inhibitor was infliximab (95% of 
episodes) and the median follow-up time was 1.0 years among TNF-α inhibitor episodes 
and 2.1 years among no-use episodes. During follow-up, in the unweighted episodes of 
current TNF-α inhibitor use and no use there were 41 and 262 serious infection events, 
respectively (Figure 6). This translated to incidence rates of 54.6 and 61.9 events per 
1000 patient-years among TNF-α inhibitor and no-use episodes, respectively, in the PS 
weighted cohort. There was no significant association between use of TNF-α inhibitors 
and the risk of serious infection, HR 0.81 (95% CI 0.54 to 1.21), and the absolute rate 
difference was -12.0 (95% CI -28.6 to 13.0) events per 1000 patient-years. Only 
considering the first 90 days of follow-up the weighted HR was similar, 0.76 (95% CI 
0.35 to 1.66). Additionally, a similar result was observed in a replication of the analysis 




Figure 6. Study II: Cumulative incidence of serious infection in weighted cohort of TNF-α 
inhibitor and no-use episodes 
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TNF-α inhibitor 618 288 146 75

































Hazard ratio 0.81 (95% CI, 0.54 to 1.21) 
 
36 
4.3 STUDY III: DATA MINING FOR ADVERSE EVENTS OF TUMOR NECROSIS 
FACTOR-ALPHA INHIBITORS IN PEDIATRIC PATIENTS 
4.3.1 Background 
Although TNF-α inhibitors are efficacious and considered safe in adults,32-34 the 
pediatric-specific safety data is generally scarce. Previously unknown adverse events 
can be detected post-market approval when drugs are used by a more heterogenous 
and larger set of patients in clinical practice. Traditionally, spontaneous reporting 
systems have been the main source for signal detection. The use of routinely-collected 
data from health registers is another opportunity, which enables data mining at a large 
scale with potentially lower risk of reporting bias and confounding. The aim of study III 
was to screen for signals of previously unknown adverse events of TNF-α inhibitors in 
Danish pediatric patients with IBD or JIA, applying data mining methods to nationwide 
health care registers. 
4.3.2 Key results  
Based on Danish nationwide data, we identified 1310 episodes of new TNF-α inhibitor 
use in pediatric IBD and JIA patients. In a PS matched tree-based scan statistics analysis 
with episodes of no use as comparator, we detected two signals of adverse events of 
TNF-α inhibitors: dermatologic complications (ICD-10: L00-L99, 87 Vs 44 events, risk 
difference [RD] 3.3%) and psychiatric diagnosis adjustment disorders (ICD-10: F432, 33 
Vs 7 events, RD 2.0%) (Table 3). The former events have been described previously in 
adults and children, while the latter was likely associated with the underlying diseases 
and their severity, rather than with the treatment. We also performed a self-controlled 
scan statistics analysis that generated no signals. Hence, no signals of previously 
unknown adverse events of TNF-α inhibitors in pediatric patients were detected. The 
analysis showed how Scandinavian health care registers and novel data mining 
methods can be used to screen for previously unknown adverse events. This type of 
evidence can play a particularly important role in pediatrics where output of both 



















F432 Adjustment disorders 33 7 4.71 2.0 0.002 
L20-L30 Dermatitis and eczema 34 8 4.25 2.0 0.004 
F40-F48 Anxiety, dissociative,  
Stress-related, somatoform, etc. 
39 11 3.55 2.1 0.007 
F43 Reaction to severe stress,  
and adjustment disorders 
35 9 3.89 2.0 0.008 
L00-L99 Diseases of the skin  
and subcutaneous tissue 
87 44 1.98 3.3 0.017 
 
Table 3. Study III, PS matched analysis: Plot; dendrogram on all cuts of the ICD-10 tree with 
at least one event in the TNF-α inhibitor episodes or the no-use episodes (down to the 




4.4 STUDY IV: SELECTION OF COMPARATOR GROUP IN OBSERVATIONAL 
DRUG SAFETY STUDIES 
4.4.1 Background 
The comparator group is a key element of the design in pharmacoepidemiologic 
studies.86 The active comparator new user (ACNU) design is a commonly used design 
where the comparator consists of patients initiating another drug at baseline.87,88 This 
design has high potential to reduce various types of bias, but it also has limitations, 
including the requirement of a suitable comparator drug and strict eligibility criteria. In 
this study we explored and evaluated the following alternative designs that can be used 
when ACNU is not optimal: traditional no use, no use episodes, prevalent new user, 
generalized prevalent new user, and hierarchical prevalent new user. We used target 
trial emulation as a mutual framework to facilitate comparison of the designs. The 
specific aims of study IV were to systematically describe and compare alternative 
pharmacoepidemiologic designs, and to present a case example where the designs are 
applied in a real-world drug safety assessment to illustrate the differences. 
4.4.2 Key results  
In this study, we showed how the target trial emulation framework and sequential 
cohorts can be used to transparently communicate and compare various study designs 
in pharmacoepidemiology: the key difference between the designs is the eligibility 
criteria at baseline (Figure 7). From scrutinizing the differences and applying the 
designs in a case example, we concluded that many study-specific factors influence the 
selection of optimal comparator, including indication, available comparator drugs, 
treatment patterns, potential effect modification, and sample size. The ACNU is superior 
in its potential to reduce confounding and information bias, but if the strict eligibility 
criteria impair generalizability or statistical precision, a prevalent new user design 
might be preferable. If there is no suitable active comparator drug available a no use 
design can be considered. Irrespectively of the chosen design, the risk of bias needs to 





Figure 7. Study IV: Flow chart for identification of eligible patients (left) and eligibility for patient with sequential use of comparator and study drug 
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• No previous dispensing of the study drug
• No previous diagnosis of the outcome event
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Included comparator follow-up time
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4.5 STUDY V: TNF-ALPHA INHIBITORS AND THE RISK OF SERIOUS 
INFECTIONS IN JIA 
 
4.5.1 Background 
Previous studies have shown that serious infection is an adverse event of TNF-α 
inhibitors in adults with rheumatic disease. A meta-analysis of RCTs on biologics found 
significantly increased risks, separately restricted to TNF-α inhibitors (116 RCTs) and 
RA patients (62 RCTs).45 In JIA, there are primarily two previous studies that 
investigated this safety concern. Both were prospective, observational and analyzed use 
of etanercept: one found a significant association (n=1414; RR 2.12, 95% CI 1.08 to 
4.17)55 and the other reported an HR of 1.36 with a rather wide CI (n=852; 95% CI 0.60 
to 3.07).56 Hence, the pediatric-specific safety evidence is limited. The aim of study V 
was to investigate if there is an association between the use of TNF-α inhibitors and the 




Figure 8. Study V: Cumulative incidence of serious infection in weighted cohort of TNF-α 
inhibitor and MTX users  
 
4.5.2 Key results  
Based on Danish nationwide data, among patients with confirmed JIA we identified 578 
initiators of TNF-α inhibitors who met the eligibility criteria. The comparator consisted 
of 1915 observations of initiators and users of MTX. In the unadjusted cohort, the mean 
age (SD) was similar between the TNF-α inhibitor and MTX groups, 11.7 (4.2) and 11.8 
(4.3) years, respectively. The distribution of females was the same, 71% in both groups. 
Number at risk
TNF-α inhibitor 578 234 125 64































Hazard ratio 1.99 (95% CI, 1.09 to 3.65) 
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However, comorbidities and JIA complications were generally more prevalent in the 
TNF-α inhibitor group. The proportion that was incident to MTX at baseline was 36% 
and 24% in the TNF-α inhibitor and MTX group, respectively. The mean (SD) follow-up 
was longer in the MTX group, 2.2 (1.1) compared with 1.2 (1.0) years. During follow-up 
in the unweighted cohort, we observed 26 events of serious infection among the TNF-α 
inhibitor users and 75 events in the MTX group. This translated to incidence rates in the 
TNF-α inhibitor and MTX groups of 4.0 and 1.9 events per 100 patient-years, 
respectively, in the PS weighted cohort (Figure 8).  We observed a significant 
association between the use of TNF-α inhibitors and the risk of serious infection, HR 
1.99 (95% CI 1.09 to 3.65). The site-specific infections with increased risk were 











5.1 CLINICAL IMPLICATIONS 
In study I, we found that the use of azathioprine in pediatric IBD significantly increased 
the risk of acute pancreatitis by almost six times during the first 90 days following 
azathioprine initiation, as compared with no use. The relative risk was similar to the 
results from two previous studies in adults,39,82 while the absolute risk was lower than 
findings from several observational studies and clinical trials in adults.37-40,83,84,89 This 
discrepancy could be due to differential risk factors of acute pancreatitis, where 
gallstone, smoking and alcohol misuse are some of the most important risk factors in 
adults. Acute pancreatitis is a very rare condition in the general pediatric population 
and a meta-analysis in adults showed that IBD is a risk factor; a two- to four-fold 
increased risk depending on IBD subtype was observed, in comparison with the general 
population.90 Another similarity with the findings in adults was the short time to onset 
of acute pancreatitis among azathioprine patients (median 23 days in our study), which 
supports the notion of an association and a similar mechanism between the patient 
groups. However, the pathogenesis of thiopurine-induced acute pancreatitis is 
unknown. A few potential mechanisms have been suggested, including accumulation of 
toxic metabolites, immunological reactions, and genetic predisposition.91  
Thiopurine-induced cases of acute pancreatitis in adults have been described as 
comparably mild.40 Withdrawal of thiopurine treatment is indicated following onset of 
acute pancreatitis, which in most cases leads to alleviated symptoms. This was 
supported by the results of our study where the duration of hospital stay of inpatient 
acute pancreatitis cases was shorter in the azathioprine episodes in comparison with 
the no-use episodes (median length of stay was 5.1 and 18.4 days, respectively). The 
increased risk of acute pancreatitis shortly following treatment initiation supports the 
current practice of frequent monitoring of pediatric IBD patients during this period. 
Regular tests of thiopurine-related metabolites and enzymes, including thiopurine 
methyltransferase (TPMT), supports optimal dosing and reduces the risk of adverse 
events, such as acute pancreatitis, in these patients.92  
In studies II and V, we investigated if there is an association between use of TNF-α 
inhibitors and the risk of serious infections in patients with pediatric IBD and JIA, 
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respectively. The analysis in pediatric IBD showed no significant association between 
the use of TNF-α inhibitors and the risk of serious infection, as compared with no use. 
Whereas the study in JIA found a significant two-fold increased risk associated with 
TNF-α inhibitors, as compared with MTX. 
There are more available pediatric-specific data on this safety concern in JIA than in 
IBD. Our results in JIA were similar to what has been shown previously in two 
prospective studies.55,56 All studies had comparably small sample sizes, but taken 
together they give a coherent picture of an increased risk of serious infection among JIA 
patients who initiate TNF-α inhibitors, in particular infections of the respiratory tract 
and skin. Further, the increase in relative risk is also similar to what has been reported 
in meta-analyses of RCTs in adults.45 
In pediatric IBD, there is only one previous controlled study, which was conducted 
based on insurance claims data in the United States, that offers relevant comparison.51 
Similar to our analysis, this study found no significant association between the use of 
TNF-α inhibitors and the risk of serious infection in children. The absolute rates of 
serious infection among users of TNF-α inhibitors were also similar between the 
studies. Considering the results together, they indicate that use of TNF-α inhibitors 
might be associated with a smaller increased risk of serious infection in pediatric in 
comparison with adult IBD, if any at all.  
The factors that influence the variable risk of serious infection following use of TNF-α 
inhibitors need further investigation. Potential aspects are the baseline infection risk, 
timing of initiation during the disease course, specific biologics used, and use of 
combination treatments.93 Intravenously administered infliximab was the predominant 
TNF-α inhibitor agent in pediatric IBD, whereas subcutaneous adalimumab and 
etanercept were the most common in JIA. The baseline risk of infection varies greatly 
between age groups of children and in relation to adults. The characteristics of 
underlying disease, including its severity and extent, are also important risk factors. The 
severity of IBD is generally higher in patients with childhood onset IBD in comparison 
with adult onset.94 The disease manifestation and prognosis also affect treatment 
strategies and the timing of initiation of TNF-α inhibitors. As described above (section 
2.1), TNF-α inhibitors are used earlier in the disease course and to a larger extent in 
pediatric IBD than in JIA. Comparisons with adult IBD patients have shown more 
widespread use of TNF-α inhibitors in children.18 From a global perspective, it is also 
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evident that the use of TNF-α inhibitors is more prevalent in the United States in 
comparison with Europe.95 
Traditionally bottom-up treatment strategies have been used in both pediatric IBD and 
JIA, where available pharmacologic therapies form a pyramid with less efficacious but 
safer treatments at the bottom and more potent but potentially more toxic treatments 
at the top.30,96 Treatment starts at the bottom of the pyramid in newly diagnosed 
patients and is stepped up if tolerability is low or the treatment response is not 
sufficient. Critical steps in this strategy are the initiations of thiopurines in pediatric 
IBD, which are more potent than 5-ASA, and MTX in JIA. Followed by the option to add 
or switch to a TNF-α inhibitor or other biologic at a later point, which represent the top 
of the pyramid.  
This approach has, however, been contested by alternative treatment strategies where 
either treatment is stepped up faster and initiation of biologics occurs earlier in the 
disease course or a top-down approach, where biologics are initiated before or 
concomitantly with thiopurines or MTX.30,96 The rationale for a top-down strategy is 
based partly on the, at least short-term, favorable safety profiles of TNF-α inhibitors, 
and partly on the notion that the efficacy of these treatments and the chance to 
positively alter the disease course are higher at an early stage. 
For particular patient groups, such as severe CD with anal fistula, polyarthritis with high 
disease activity, and systemic JIA, early initiation of biologics is generally considered 
favorable.30,94 In other patient groups, the optimal treatment strategies are less distinct. 
A challenge in the top-down approach is to distinguish the pediatric IBD and JIA 
patients with worse prognosis and elevated risk of an aggressive disease course, who 
could benefit most from early use of biologics.30,97 
Considering the risks of adverse events is key when determining a suitable treatment 
strategy. The safety profiles of thiopurines, TNF-α inhibitors, and potential concomitant 
use in children critically impact the choice and timing of therapies. The results from 
studies I, II and V can support clinical decision-making and need to be considered when 
weighing potential benefits against risks when prescribing to children with pediatric 
IBD or JIA. Important avenues for future research include safety assessments from other 
health settings, based on larger pediatric cohorts, and with focus on subgroups that 
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might be at higher risk of acute pancreatitis and serious infections, in particular disease 
subtypes, age groups, and patients at different steps of the traditional treatment ladder. 
 
5.2 METHODOLOGICAL CONSIDERATIONS 
 
5.2.1 New-user design 
Pharmacoepidemiologic studies on the safety and effects of drugs are typically cohort 
studies based on longitudinal data. A seemingly minor design feature that has 
significantly improved the quality and relevance of these studies during the last two 
decades is the new-user design.98 To make a valid assessment of the effect, new 
(incident) users of a drug must be studied rather than prevalent users. It is critical to 
identify the time point of treatment initiation and define time at risk from this point.  
There are primarily two advantages of this design. First, the effect of the drug can vary 
over time and excluding a time interval following initiation can bias the effect estimate, 
e.g. excluding the time shortly following treatment initiation when studying an acute 
allergic adverse reaction. There are many examples of effect assessments that have 
been biased due to not studying new users.99 We used a new-user design in all studies, 
I-V.  In study I, we found a significant association between the drug and the outcome 
within the first three months following treatment initiation and no association in the 
secondary time window, months 4-12. Hence following patients from the initiation of 
the drug was critical to correctly capture the adverse effect of the drug. Second, patients’ 
covariate status needs to be assessed only based on information available before drug 
initiation for appropriate confounding control. For example, if we adjust for disease 
severity status (X) that is evaluated after drug initiation, it could be affected by drug use. 
If disease severity in turn affects the risk of the outcome (Figure 9; graph a) it is a 
mediator and we will not estimate the total effect of the drug (A on Y). In another 
scenario, disease severity post baseline shares cause (U) with the outcome and 
adjusting for it induces selection bias (Figure 9; graph b). Characterization at treatment 
start, when patients in most cases have been in recent contact with a physician, also 





Figure 9. Directed acyclic graphs (DAG) on scenarios of conditioning on post baseline 
disease status (X), where X is a mediator (graph a) or a collider (graph b). A, drug 
exposure; Y, outcome; U, unobserved factors causing X and Y. 
 
Identifying the time point of drug initiation can be non-trivial because data on drug use 
is rarely complete retrospectively, i.e. from birth to observed drug use. In practice a 
look-back period is used and drug initiation is defined as a filled drug prescription or a 
drug administration that was not preceded by another prescription fill or 
administration during a fixed time window before (e.g. two years). The possibility to use 
a longer look-back window depends on the data source and the duration patients are 
enrolled. Shorter look-back periods are typically used in analyses based on insurance 
claims data where disenrollment is more frequent than in national registers (where 
patients generally are disenrolled only due to emigration). Pediatric patients commonly 
have shorter disease and treatment history and fewer comorbidities that require a long 
look-back period to capture. In our data, a large share of patients’ history is covered 
and, in many cases, we have complete look-back to birth. Thus, timing of drug initiation 
and covariate status can be assessed with higher accuracy in pediatric patients and 
particularly when using data from national registers. 
 
5.2.2 Target trial emulation  
Target trial emulation is a framework for conducting observational studies by relying 
on concepts and methods from RCTs.75,76 In this framework, an observational study is 
designed by mimicking a hypothetical target trial; the experiment that we would have 
conducted if it was practically possible. The target trial is emulated element by element 









outcome definition) to clearly and transparently communicate what is actually done 
and to avoid unnecessary bias caused by inappropriate design.75,76 In study IV, we used 
target trial emulation as a common framework when defining and analyzing differences 
between alternative pharmacoepidemiologic designs. In study V, we used the concept of 
a pragmatic trial as a blueprint for the design and used sequential cohorts and a 
generalized prevalent new user design (described in study IV).  
The target trial emulation framework is particularly useful in pharmacoepidemiology, 
where analyses often share purpose, exposure and terminology with clinical trials – 
even when the framework is not explicitly used. Evidence from pharmacoepidemiologic 
studies can be extensions of and complement real clinical trials. Emulating a target trial 
is sensible because longitudinal and routinely-collected observational data from 
multiple sources are often complex. Identifying a suitable start and end of follow-up for 
each patient is not trivial and the lack of prospectively collected data makes patient 
status at different time points often indistinct. Relying on the structure of clinical trials 
makes critical design decisions more rigorous and ensures that we analyze 
retrospective data with a prospective point of view.  
Certain aspects of the target trial emulation framework are particularly valuable. 
Eligibility criteria that are clear, applied consistently and only based on information 
known at baseline are key. A useful tool to synchronize eligibility, treatment 
identification and start of follow-up at baseline is sequential cohorts that are defined 
repeatedly over the follow-up period and resemble a series of repeatedly conducted 
trials. With this approach, the baseline (time zero; index date) for each sequential 
cohort is clearly defined and various time-related biases are avoided (Figure 10).76 
 
 
Figure 10. Sequential cohorts defined in discrete intervals over the study period 
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Period with available data from all data sources
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Week 1 Week 520
Example: sequential cohort 130 (February 1-7, 2010)
Baseline at week 130: covariate status, eligibility and exposure




Further, allowing repeated eligibility and entry over follow-up is an efficient way of 
using observational data,100 which is particularly relevant in analyses of small samples 
such as in pediatric drug safety studies. To be able to follow each patient from multiple 
start dates that differ in terms of current and previous treatments, history of 
complications, disease progression, and obviously age, as opposed to selecting only one 
baseline per patient, adds relevant data to the analysis. The mean length of follow-up in 
the cohort of patients with confirmed IBD or JIA disease was 4.4 years. However, 
repeated inclusion of individual patients is not a requirement when using sequential 
cohorts; patients who once were eligible can be excluded from subsequent cohorts. 
 
5.2.3 Comparator 
Exposed patients are compared with a set of patient observations: the comparator 
(unexposed; control group). Simply put, the ideal comparator contains patients who do 
not use the study drug but are as similar as possible to those who do, in particular with 
respect to factors that influence the risk of the outcome. With an ideal comparator the 
difference in risk between the groups can be attributed to the drug under study. In 
interventional studies the assignment to study drug and comparator group is 
randomized, creating balance between the groups on both observed and unobserved 
factors. In observational studies the comparator definition is a critical element of the 
design, which is rarely straight-forward and can have a large impact on the results.86  
In study IV, we investigated the pros and cons of different study designs commonly used 
in pharmacoepidemiology and the conditions that affect the selection of comparator in a 
particular study. Specifically, we looked at viable alternatives to the ACNU design, 
including traditional no use, no use episodes, prevalent new user, generalized prevalent 
new user, and hierarchical prevalent new user. The ACNU is often described as a robust 
standard for evaluating safety concerns.87,88 The ideal active comparator is a drug with 
the same indication as the study drug, that targets patients with similar disease severity 
and frailty, and with no known association with the outcome. Only patients who are 
naïve to both the study drug and the comparator drug are included in the analysis. 
An advantage of the ACNU design is that it can reduce confounding, both observed and 
unobserved, by using patients with the same indication. Another advantage is that 
patients followed from initiation of the study drug or the comparator drug will be 
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temporally aligned; they had recent contacts with health care, are in similar phase of 
disease development and have had similar information collected. The ACNU design can 
also be used to assess the comparative safety between two drugs where the comparator 
drug is not necessarily without known association with the outcome. 
There are also disadvantages to the ACNU design. First, it can be difficult to find a 
suitable active comparator drug: comparator drug candidates within the same 
indication might target different patients or have an effect on the drug studied. Second, 
only study drug initiators who have not previously used the comparator drug are 
eligible, which can lead to extensive exclusion, leaving a too small and possibly not 
representative sample of patients for analysis. This typically occurs when treatments 
are given in sequence, e.g. when a new drug is introduced and there is channeling to it 
from the previous standard of care, or when patients switch between treatments due to 
lack of response or adverse events. In the end, the ACNU design was not used in any of 
the studies of this project because of the eligibility requirements. For instance, in study 
I, a potential active comparator drug was 5-ASA. If we had compared azathioprine 
initiators with 5-ASA initiators using ACNU in study I, we would have excluded 68% of 
the azathioprine group due to previous 5-ASA use. Given the few events that occurred in 
these patients, this analysis would have been practically impossible to perform. 
This limitation of the ACNU design was addressed by Suissa et al in 2017.74 In the 
prevalent-new user design, initiators of the study drug are compared with new and 
prevalent users of the comparator drug. The study drug initiators (both incident and 
prevalent to the comparator drug) are matched with comparator initiators and 
prevalent users in strata based on the extent of previous treatment with the comparator 
(defined based on treatment duration or number of prescriptions) on time-dependent 
PS, i.e. stratified PS models. The matching is performed prospectively, starting with the 
first strata (patients who are incident to the comparator). Individuals with comparator 
observations can only be matched once, ensuring that outcome events are not 
accounted for repeatedly in the analysis. Hence, with this design the ACNU cohort (no 
previous use of the comparator) is analyzed and strata with varying extent of use in the 
comparator are added, which can be analyzed separately or pooled. In the patients who 
are prevalent in the comparator, the contrast between switching to or adding the study 
drug and staying on treatment with the comparator drug is assessed. 
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In study IV, we also looked at two other prevalent new user designs. The generalized 
prevalent new-user design is less restrictive than the design proposed by Suissa et al, 
applying the same eligibility criteria but not requiring time-dependent PS matching. 
Instead, patients can contribute with repeated observations to the comparator group 
(more than one stratum), which means that follow-up time and potential events are also 
included repeatedly. This approach is less restrictive in the sense that no exclusion of 
observations due to lack of match or because another observation from the same 
individual had already been matched. This can increase efficiency, generalizability and 
make it possible to use different methods for confounding control, including PS 
weighting, and estimate different types of effects, e.g. ATT and ATE. In study V, we 
applied the generalized prevalent new user design, in order to use MTX as active 
comparator while not excluding TNF-α inhibitor initiators who had previously used this 
drug (65% of all initiators). 
We also described the hierarchical prevalent new-user design, which is sometimes 
simply referred to as a ‘new user’ design.54,101-105 In this design, eligibility criteria are 
applied differentially depending on baseline exposure: patients who are prevalent in the 
comparator are excluded from the comparator group, but not the study drug group. 
Analogously, if this design was applied in a clinical trial, both patients who were 
incident and prevalent to the comparator drug would be enrolled, but only the incident 
would be randomized (to either the study drug or the comparator drug). The prevalent 
patients would be automatically assigned to the study drug. If previous treatment with 
the comparator or characteristics of that treatment history (time since initiation, 
cumulative dose, etc.) are confounders they cannot be adjusted for due to the 
deterministic violation of positivity; among prevalent patients the true PS is one.106 
The potential bias in the hierarchical prevalent new-user design depends on what 
previous use of the comparator represents and many different scenarios are plausible. 
In one scenario, use of the comparator increases the risk of the outcome (contrary to the 
standard criteria for a suitable active comparator), which means that patients with 
previous use and no previous outcome event represent survivors and potentially have 
lower risk of the outcome. In a second scenario, there is no effect of the comparator 
drug, but previous use is a positive proxy for disease severity, which increases the risk 
of the outcome. In an opposite third scenario, continuous previous use is a negative 
proxy representing healthy users who have lower risk of the outcome. Irrespective of 
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what previous use in the comparator represents, previous use of a comparator drug 
commonly contains information about risk factors for which adjustment is necessary. 
Despite the risk of bias, the hierarchical prevalent new user design is surprisingly 
common in pharmacoepidemiology; possibly because it solves the fundamental 
challenge of using an active comparator while not excluding those who are prevalent in 
the comparator drug.  
Finally, we also investigated the less restrictive no-use designs, where the comparator 
group consists of patients with the same underlying disease as the study drug initiators 
and with neither current nor recent use of the study drug.86 No use designs are 
commonly misunderstood; possibly due to inappropriate application in the past. When 
implemented correctly, ‘no use’ simply means no use of the study drug at a certain time 
point and during a set look-back period before. It does not mean no use of any 
pharmaceutical drug or no use of the study drug during the entire study period, which 
could introduce selection bias. The use of multiple sequential cohorts with repeated 
baselines during the study period, as described in section 5.2.2, facilitates transparent 
and unbiased assignment of index dates. 
In study IV, we included a traditional no use design that served as a template for the 
other designs since the eligibility criteria were basic (indication, no previous study drug, 
no previous event) and all other designs were nested within it. Similarly, to the 
generalized prevalent new user design, overlapping follow-up time and events are 
included to use the data in the most efficient way. In contrast, in the no use-episode 
design that was used in studies I-III, all study drug users and non-users were analyzed 
in mutually exclusive episodes of follow-up. This was achieved by defining a maximum 
length of the episodes and adding to the eligibility criteria that a patient observation 
was excluded if the same patient had contributed a previous episode that was still 
ongoing. The length of episodes was set to one year in study I and three years in studies 
II and III. When applying this design, multiple episodes of both study drug use and no-
use could be contributed by the same patient, but not more than one outcome event. In 
practice the no-use episodes design can be very similar to the prevalent new-user 
design in terms of patient selection for the comparator group, especially if we condition 
on previous use of a comparator drug. However, important potential limitation of no-
use designs in relation to active comparator designs is the risk of information bias and 
confounding by indication. In study IV, we conclude that no-use designs are in particular 
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useful when no suitable comparator drug is available, which is not a rare scenario. 
Active comparator designs are generally preferred and a prevalent new user design can 
be used when ACNU requires extensive exclusion. 
 
5.2.4 Confounding by indication 
Confounding can be a major issue in observational safety studies. If factors that affect 
both exposure and outcome are not adjusted for, the association between exposure and 
outcome is confounded (Figure 11; graph a). In pharmacoepidemiologic studies, good 
clinical practice and tailored prescribing of drugs may lead to confounding by indication 
– that study drug users are systematically different from comparators with respects to 
risk factors for the outcome. Despite targeted prescribing, there are many reasons why 
similar patients do not receive the same treatment. Prescribing patterns can vary 
between geographical regions, hospitals, individual physicians, time periods and due to 
patient preference. These variations are key for being able to perform drug safety 
analyses based on observational data.  
Confounding by indication can be a stubborn bias for which adjustment is challenging. 
The difficulty in identifying comparator patients with the same indication and disease 
severity as the study drug users is one of the key reasons that active comparators, 
where confounding is mitigated by design rather than statistical analysis, are useful (as 
in study V). In studies with no-use comparators (studies I-III), robust confounding 
control needs to be achieved through the statistical analysis. Typical potential 
confounders in a drug safety study are age, sex, comorbidities, treatment history, 
disease stage, and disease severity. If data has not been collected on the identified 
potential confounders an alternative is to use proxies, i.e. factors that are highly 
correlated with the potential confounders. For example, a proxy for general health 
status is health care use, which could be measured as the number of unique drugs used 




Figure 11. DAGs of confounding adjustment based on adjusting directly for a confounder 
(graph a), adjusting for a proxy for a confounder (graph b), M bias where the factor that 
we adjust for is a collider (graph c), and both collider and confounder (graph d). A, 
treatment; Y, outcome; X, the factor that we adjust for; U, unobserved factor. 
 
5.2.5 Propensity score methods 
There are many methods to adjust for confounding, such as stratification, 
standardization, and regression analysis. PS methods, introduced by Rosenbaum and 
Rubin in 1983, are common in pharmacoepidemiology.77,107 The PS measures the 
propensity of an individual patient to be assigned treatment; the probability of being 
exposed (0 ≤ 𝑒𝑖 ≤ 1). In an RCT where all patients have equal probability of being 
assigned treatment the PS is 0.5. In observational studies the true PS is unknown, but 
we can estimate it conditioned on potential confounders in our cohort (Formula 2).  
𝑒𝑖 = 𝑃(𝐴𝑖 = 1|𝑋𝑖) 
[Formula 2] PS (𝑒𝑖) is the conditional probability of being exposed. 𝐴𝑖  baseline treatment 
(1 exposed; 0 comparator); 𝑋𝑖 vector of baseline confounders. 
 
The PS is useful in confounding control because it is a balancing score. For each value of 
















same in the exposed and comparator. Hence, information from multiple confounders is 
collapsed in the PS and balance between exposed and comparator can be achieved by 
conditioning on it, e.g. through matching or weighting. 
The key advantage of PS methods is that we can perform robust confounding 
adjustment by modelling the probability of the treatment rather the outcome. Due to 
the balancing property of the PS we can control for many confounders independently of 
the prevalence of the outcome. If we include too many covariates in relation to the 
number of events in a multivariable outcome model, we may obtain biased estimates or 
have convergence problems.108 In drug safety studies the combination of few outcome 
events and extensive confounding is common, particularly in pediatric studies. We used 
PS matching or weighting in all the studies of this project.  
 
5.2.5.1 Propensity score model estimation  
A valid PS analysis relies on a correctly specified model of the relationship between 
treatment assignment and potential confounders. The PS is commonly estimated with 
logistic regression, which was used in studies I-V, where treatment is the dependent 






[Formula 3] PS (𝑒𝑖) estimated with logistic regression. 𝑋𝑖 vector of baseline confounders; 
𝛽 vector of coefficients estimated from the data. 
 
Key diagnostics in PS analysis is the crude PS distribution, the overlap between exposed 
and comparator, and balance of individual covariates in the adjusted cohort. Differences 
and large separation of the PS distributions between the groups can indicate a 
misspecified PS model or lack of positivity, i.e. there are levels in the potential 
confounders where all are exposed or comparator observations. This can in turn be due 
to the selection of an unsuitable comparator with large differences in covariate status at 
baseline, which might also indicate imbalance in unobserved factors.  
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Covariate balance is an intuitive diagnostic of PS model performance. It can be assessed 
by calculating absolute standardized mean differences for each covariate, both 
continuous and dichotomous. This measure expresses the difference in means in units 
of the pooled standard deviation (Formula 4). A difference smaller than 10% is 
commonly regarded as well-balanced.77 Standardized differences are preferred over 








[Formula 4] Absolute standardized mean difference (𝑑). ?̅?𝐴 sample mean in covariate 𝑥 
among observations with treatment 𝐴 (1 exposed; 0 comparator); 𝑠𝐴
2 sample variance in 
covariate 𝑥 among observations with treatment 𝐴. 
 
We performed this assessment in studies I-V. In the case example of studies IV, we 
plotted the standardized mean differences (not absolute) of 58 risk factors to show 
differences between comparators (only adjusted for age and sex). A positively skewed 
distribution indicated a higher observed risk in the study drug group and a negatively 
skewed distribution meant a lower risk. 
Additionally, a more granular assessment of balance can be performed for continuous 
variables by comparing empirical cumulative density functions (eCDF) in the exposed 
and comparator for visual inspection.109 In Figure 12, this is shown for the covariates 
disease duration and measures of general health care use for the crude and weighted 
cohorts in study V. The difference in eCDF can also be quantified with the Kolmogorov–
Smirnov statistic, which is the maximum vertical distance between the eCDF in the 





Figure 12. Diagnostics of baseline covariate balance in study V: empirical cumulative 
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An advantage with PS methods is that alternative PS models can be assessed and 
compared against each other without involving the outcome. In the study cohort, 
alternative methods for PS estimation, selection of confounders and model specification 
can be tested in order to optimize balance at baseline, before estimating the association 
between drug and outcome event. Beyond logistic regression there are numerous more 
flexible, data-adaptive methods that have been proposed to improve PS estimation and 
reduce bias, including machine and ensemble learning methods that can be applied with 
cross validation.110,111 However, logistic regression is still the most common method for 
PS estimation in applied pharmacoepidemiologic analyses. 
 
5.2.5.2 Covariate selection 
Preferably covariates for a PS model are chosen based on subject-matter knowledge 
and the assumed causal structure surrounding the drug-outcome relationship.112 Data is 
collected and adjustment is made for the identified potential confounders. However, in 
pharmacoepidemiology, where large and complex secondary data sources commonly 
are used, prospective data collection is rarely feasible. To improve confounding 
adjustment, methods for empirical covariate selection have been developed and are 
commonly used. With these methods covariates are selected, partially or solely, based 
on observed associations in the data. The rationale for using these methods is that the 
underlying causal structure is largely unknown and that confounding control can be 
improved by adjusting for large sets of proxy variables that are associated with both the 
treatment and outcome. The causal relationships and the role of the proxy variables are 
not necessarily known. 
One of the most common methods for empirical covariate selection is the high 
dimensional propensity scores113, which is an algorithm where potential baseline 
covariates are ranked univariately based on association with treatment and outcome. 
Those with the highest rank are included in the PS model; based on a predetermined 
threshold. The potential covariates or proxy variables are derived as dichotomous 
indicators of history of disease, medical procedures and treatment. Some of the 
limitations of this method are that covariates are selected independently of each other 
and the potential for overfitting.114 However, these issues can be overcome by adapting 
the covariate selection procedure and using flexible, data-adaptive methods, such as 
ensemble learning algorithms and penalized regression, rather than an univariate 
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screener.115,116 Yet, one limitation that applies to all approaches of empirically selecting 
covariates is the risk of adjusting for pre-baseline colliders, i.e. opening a backdoor path 
between treatment and outcome, and introducing selection bias. This bias is commonly 
known as M bias (Figure 11; graph c) and simulation studies have shown that the 
potential for this bias is small in relation to the bias caused by lack of adjustment for 
confounders.117 Note that a pre-baseline collider can simultaneously be a confounder 
(Figure 11; graph d), in which case adjustment is generally recommended.   
In addition to methods based on only PS estimation there are doubly robust methods, 
such as targeted maximum likelihood estimation,118 where both the treatment and 
outcome are modeled. It has been shown that this two-step procedure can optimize the 
bias-variance tradeoff in estimation of causal effects. 
 
5.2.5.3 Propensity score matching  
In studies I and III, we adjusted for confounding through PS matching. In PS matching, 
each exposed patient is matched with one or many comparator patients who have 
similar PS (within a certain absolute caliper) according to a predefined ratio, e.g. 1:1. 
Various matching algorithms are available and in the most common, greedy nearest-
neighbor matching, exposed patients are selected randomly and matched with the 
comparator patient (among those who have not already been matched) where the 
difference in PS is minimized.77 PS matching is a simple and intuitive procedure that 
allows a transparent presentation of results and balance assessment. 
In PS matching we estimate the ATT if all exposed patients in the crude cohort are 
matched. Due to lack of overlap in PS distribution or too few comparator patients, a 
completely matched cohort is rare. In practice, the estimand in a PS matched cohort is 
ATT in the exposed who were matched, which is not necessarily a distinct subset of 
patients with certain characteristics. The matched patients are indirectly defined by 
properties of the matching procedure, such as selected confounders, caliper, and 
comparator group. Exclusion due to lack of match can lead to decreased generalizability 
and precision.  
The selection of caliper in PS matching represents a tradeoff where a small caliper gives 
less bias at the expense of reduced generalizability and precision. Typically, the caliper 
is set relative to the dispersion of the estimated PS in the crude cohort, e.g. 20% of the 
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pooled standard deviation of the logit PS,77 which was used in study I where 94% of the 
exposed were matched. In study III, where we performed a data mining analysis we 
prioritized efficiency over bias reduction. We used a very large caliper and the entire 
cohort was matched, while maintaining acceptable balance on all covariates.  
Under some conditions, in particular if the sample is small a reduced caliper can 
increase bias, which has been described as the PS matching paradox.119 However, it has 
been shown that this is rare if standard caliper sizes (relative to dispersion) are used 
and it is possible to test if the analysis is susceptible to this issue by varying the 
caliper.120   
 
5.2.5.4 Propensity score weighting 
In studies II, IV and V, we adjusted for confounding with PS weighting: SMR, fine 
stratification weighting, and stabilized IPT weighting, respectively. In weighting, each 
observation is assigned a weight that is calculated based on the PS (see formulas in 
previous section 3.3.1) in order to create a weighted pseudo population. Key advantages 
of PS weighting in relation to matching are less exclusion of exposed observations, 
flexibility in terms of the estimated effect, and low computational intensity. If there are 
fewer comparator patients than exposed, weighting is the obvious choice to avoid 
exclusion.  
While lack of overlap in PS distribution between exposed and comparator leads to 
exclusion in PS matching, in PS weighting it leads to large weights. Extreme weights 
decrease precision and indicate lack of positivity or that the PS model is misspecified.109 
In contrast to PS matching, positivity violation is avoided by excluding patients with PS 
outside of the common range in PS weighted analyses. Additionally, patients with 
weights in the bottom and top percentiles, e.g. in the 1st and 99th, can be truncated to 
avoid extreme weights. However, this truncation can lead to increased bias. 
With SMR and fine stratification weighting we estimate the ATT, while we estimate the 
ATE with stabilized IPT weighting (see weighting formulas in section 3.3.1). In study II, 
we used SMR weighting to estimate the ATT because we used a no-use comparator and 
wanted to estimate the effect in those who actually received TNF-α inhibitors. In the 
case example of study IV, we used fine stratification weighting to estimate the ATT to 
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preserve the comparator sample size and estimate an effect that was as similar as 
possible between the alternative comparator analyses.  
Fine stratification has the advantage that the comparator sample size is kept and 
extreme weights can be avoided by using a lower number of strata (note that there is 
also an ATE version of fine stratification weighting that was not used in this project). In 
study V, where we used an active comparator and the treatment groups were fairly 
similar at baseline we estimated the ATE. IPT weighting is the most commonly used PS 
weighting method and is a part of g methods (generalized methods which are also 
applicable in analyses of time-varying exposure) and targeted maximum likelihood 
estimation.118 
 
5.2.6 As-initiated and as-treated analyses 
As in clinical trials, patients can be analyzed based on the treatment assignment at 
baseline (intention-to-treat) or based on the treatment actually received during follow-
up, i.e. following the patients who adhere to the assigned treatment strategy and as long 
as they adhere to it (per-protocol). In the observational setting, the analyses 
corresponding to intention-to-treat and per-protocol may be referred to as-initiated and 
as-treated, respectively. In the as-initiated analysis patients are followed from baseline 
where a certain drug is initiated or not (there is no information on intended treatment) 
to the end of follow-up with no censoring due to treatment changes. In the as-treated 
analysis patients are censored if they deviate from the treatment strategy at baseline, 
typically at treatment stop or change to the other drug. In the unrealistic scenario of 
perfect adherence, the analyses yield the same result.  
In practice, both analyses are susceptible to bias. Non-adherence leads to exposure 
misclassification and dilution of a possible effect in the as-initiated analysis. In the as-
treated analysis, censoring of non-adherent patients can be informative and cause 
selection bias. For example, if frail patients have a higher risk of stopping treatment the 
proportion of frail patients will decrease over follow-up. Frailty might be a risk factor 
and differential between exposed and comparator. As in RCTs, the as-initiated analysis 
is commonly used to avoid selection bias. In studies with long maximum follow-up, an 
as-treated analysis can be preferable to avoid extensive misclassification of exposure. 
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Further, if the studied adverse event is suspected to occur while patients are on active 
treatment this approach is also preferred.  
In studies II and III, TNF-α inhibitor episodes were censored as treatment stop and no 
use-episodes were censored if any TNF-α inhibitor was initiated. An as-initiated 
analysis was performed as a sensitivity analysis in study II. In study V and the case 
example of study IV, we performed as-treated analyses and attempted to mitigate 
potential selection bias from informative censoring of patients who changed treatment 
by reweighting observations repeatedly over follow-up. We used IPC weighting where 
the weight of a certain patient and time interval during follow-up is calculated as the 
inverse of the conditional probability of not being censored in the previous interval.78 
Consequently, patients at risk were assigned weights at each time interval so that they 
also represented the censored patients; including their distribution of risk factors for 
the outcome.  
IPC weighting is a fairly intuitive method that is conceptually similar to weighting used 
to adjust for confounding. While baseline confounding adjustment is taken for granted 
in observational studies, IPC weighting and other similar methods used to adjust for 
selection bias in an as-treated analyses are underutilized.121 Adjustment post baseline 
requires the splitting of follow-up discrete time intervals with time-updated covariate 
status that make the analysis more computationally intensive. However, given the 
issues with both as-initiated and as-treated analyses it makes sense to estimate both 
effects, adjust for potential informative censoring in the latter, and to apply variable 
time windows to give a comprehensive picture of the true potentially adverse effect of a 
drug.  
 
5.2.7 Data mining with scan statistics  
In study III, we performed a data mining analysis to detect signals of adverse events of 
TNF-α inhibitors. We used newly developed PS matched tree-based scan statistics and 
tree-temporal scan statistics in a self-controlled analysis. A key feature of these methods 
is the a priori unrestrictive designs. The investigated potential adverse events were not 
specified: all diagnoses in the ICD-10 tree were considered (except diagnoses that could 
not be caused by a drug, e.g. congenital malformations) and there was no restriction in 
terms of diagnosis granularity. The self-controlled analysis was additionally 
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unrestricted in terms of the risk windows that were analyzed. We tested a global 
hypothesis: is there any potential adverse event with an elevated risk in the exposed, as 
opposed to no elevated risk in any of the potential events. Hence, a large number of 
potential adverse events were screened, while adjusting for multiple testing to correctly 
estimate p-values.  
We adjusted for basic confounders in the PS matched analysis. Confounding adjustment 
is commonly left out of signal detection studies due to lack of data on covariate status. 
The confounding adjustment in the PS matched analysis was static, i.e. we adjusted for 
the same covariates in the same matched cohort in relation to all events. In the self-
controlled analysis, we adjusted for time-fixed factors through the study design. The 
selection of potential confounders in a data mining study of more than 1000 potential 
events is not straight-forward. We adjusted for general confounders that could 
influence the risk of many types of events to increase the relevance of the results and 
avoid generating spurious signals. However, the aim of the analysis was not to infer 
causality between exposure and events. New signals generated by the analysis needed 
to be evaluated by researchers with subject-matter knowledge and possibly 
investigated further with traditional pharmacoepidemiologic drug safety designs based 
on other data sources. In a recent study,86 three confounder selection strategies were 
evaluated in data mining of adverse events of four drugs using an active comparator 
design: general covariates, confounders selected with a data-adaptive approach, and 
covariates tailored to the drug pair studied that were selected by the investigator. It was 
concluded that confounder selection had little impact on the identified signals and there 
was a tradeoff between power and extensive confounding adjustment.  
A key challenge in adverse event screening is the handling of dependent events. There is 
deterministic dependence between cuts at different levels in the diagnosis tree, i.e. an 
event automatically generates events in ancestor nodes. This dependence is accounted 
for in the estimation of p-values by using the same structure in the data simulated 
under the null hypothesis. Handling repeated and potentially dependent events within 
patients is less straight-forward. One approach is to not include more than one event 
per patient in the analysis by, for example, choosing either the event that occurs first, 
the rarest, or that which is the most serious event.81 However, this omission of data 
leads to decreased power and might result in true signals going undetected. There are 
also difficulties in prioritizing between events, which contradicts the generally 
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unrestrictive nature of this type of analysis. In study III, all events were included in the 
analysis and we accounted for dependence between events within ICD-10 chapters by 
regarding these events as clusters that were randomized together either to the exposed 
or the comparator in the simulation under the null hypothesis. Potential clusters of 
adverse events signals need to be evaluated based on medical and clinical experience.  
 
5.3 ETHICAL CONSIDERATIONS 
Drug safety research in children poses many ethical considerations. RCTs represent the 
gold standard for evidence generation on safety and efficacy. However, the enrollment 
of children in RCTs of drugs that have yet not been thoroughly tested involves risks. It 
poses an ethical dilemma: evidence from clinical trials is needed to improve treatment 
of sick children, but generating that evidence would put sick children at risk. Children 
are a vulnerable patient group and consent is commonly given on a child’s behalf by 
their parents. Not surprisingly, clinical trials in severe diseases where there are few or 
no treatment alternatives can more easily enroll pediatric patients.  
Not enrolling pediatric patients in RCTs is also an ethical position. This effectively 
passes the decision of using a drug on to clinicians who potentially will use it off-label 
based on extrapolated evidence from adults, which certainly also involves risks. It also 
means that some efficacious and safe drugs are withheld from the use in children. The 
perception of potential harm of RCTs versus off-label use can be deceiving. Use in a 
large number of patients in clinical practice based on many individual treatment 
decisions dispersed over time can seem less harmful than conducting a single RCT that 
includes a small number of patients, although the former involves more potential harm 
overall. Regardless of whether RCTs are conducted, a positive consequence of use in 
clinical practice is that it generates observational data, which can contribute to 
pharmacoepidemiologic analyses and safer use in the future.  
Conducting observational drug safety studies, such as the analyses of this project, are 
not void of ethical concerns. The primary potential harm to patients comes from the 
mishandling of their personal medical data; such as violation of privacy and unethical 
use of data against their interest. Scandinavian health registers are population based 
and include all persons who receive general-access healthcare, unless they actively opt 
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out of the registration of their personal data. Patients whose data is used in 
observational studies are often unaware of this aspect of the health care system; 
consent is not required and not actively sought. Register data is anonymized by register 
holders before being distributed for research purposes. However, there is still a risk 
that individuals are identified based on the detailed information that the register 
contain. The risk of reidentification increases with more sophisticated and detailed data. 
For example, if date of birth, sex, municipality, income of both parents and disease 
history of a person are known, that information can narrow down a gross cohort of 5.3 
million unique children in Denmark and Sweden to very few, especially for individuals 
residing in less populated areas. Furthermore, algorithms for reidentification are 
becoming increasingly advanced, which increases the threat.122  
Besides the violation of patients’ privacy, reidentification can enable unethical use of 
personal data. Both government and private organizations could have incentives to use 
the data against patient interest, e.g. insurance companies could discriminate against 
clients with preexisting conditions, employers could discriminate against current or 
potential employees, and legal authorities could use the data within investigations. The 
potential harm of unethical use of patient-level medical data today and in the future is 
complex and difficult to review. Nevertheless, the level of detail on each individual and 
the lack of aggregation, which enables potential reidentification, are key to performing 
high-quality drug safety analyses; in particular, to achieve robust confounding control. 
To be able to track individuals in terms of drug use, medical procedures, diagnoses, and 
timing of health care contacts is crucial to establish causal relationships between drug 
use and adverse events.  
These legitimate interests at stake need to be weighed against one another. On the one 
hand, there is the potential benefit of this project: new safety evidence for treatments in 
common and serious diseases in children that can support clinical decision making and 
potentially lead to better patient outcomes in the future. On the other hand, there is the 
need to protect patients against potential unethical use of their data and violation of 
patient privacy. Preventive measures have been taken to mitigate the potential harm, 
such as data storing on secure servers, granting access only to researchers who perform 
data analysis, and not publishing results for individual patients, irrespectively of detail 
level. Given the potential benefit of these studies, the actions to protect the data, and the 
 
65 
relatively low risk of a data breach and reidentification, we think the potential good 
clearly outweighs the potential harm of this thesis project. 
 
5.4 POINTS OF PERSPECTIVE  
In this section we elaborate on how the generation of high-quality pediatric-specific 
drug safety evidence can be improved in the future. 
 
5.4.1 Data sourcing 
Scarce data puts a fundamental restriction on drug safety analyses. It can be a barrier in 
studying rare events, having necessary precision in our estimates, being able to study 
effect modification between subgroups of patients, and performing robust confounding 
control, both through the design and the statistical analysis. However, small sample size 
is common and expected when studying a subgroup of patients, such as children, where 
disease and drug use prevalence is lower than in the adult population.  
When sourcing data there is typically a tradeoff between population size and data 
granularity: a large cohort that is needed to study a rare event has less detailed data on 
individual patients. The relevance of drug safety analyses in pediatrics would be vastly 
improved if this hurdle could be overcome with improved data recording procedures, 
centralized collection and international collaborations. In the future, multi-national 
pooled, harmonized cohorts with clinical data, including electronic medical chart data, 
laboratory test results, and patient-reported outcomes could be generated. Based on 
such data sources it would be possible to study rare events, even in subgroups of 
children, such as relevant age strata, while maintaining robust design and confounding 
control. 
 
5.4.2 Adverse event data mining 
Data mining for adverse events based on health registers, as shown in study III, is a 
promising source of pediatric-specific drug safety information. If data sources are 
extended and direct reporting to authorities is enabled this could replace the 
spontaneous reporting systems in the future. With regular, time-updated screening of 
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health registers where diagnoses, and separately recorded suspected adverse events, 
are routinely reported, the identification of new signals can be instantaneous and 
relevant comparator groups can be generated for robust confounding control based on 
the same data source. This type of real-time post-approval surveillance analyses based 
on health registers can identify signals of adverse events of drugs used both on and off-
label in children earlier and with higher accuracy than previously.  
In such a setting, novel methods will be needed to improve statistical efficiency. The PS 
matched tree-based scan statistics approach applied in study III is fairly restrictive, 
which can reduce the usefulness in pediatrics. As noted above (section 5.2.5), PS 
matching can reduce power through exclusion of study drug users without a match. 
Further restriction comes from censoring to harmonize follow-up within matching 
clusters and in combination with an ACNU design where study drug initiators who have 
previously used the comparator are excluded.80,123 
The scope for performing signal detection against a comparator with scan statistics 
outside of the PS matching framework might be more suitable in pediatrics and requires 
further investigation. Ideally, a more general framework based on repeated inclusion of 
comparator patients and PS weighting for confounding control would be useful to 
increase efficiency. Naturally, such an approach would increase the level of dependency 
between events (repeated eligibility of individual patients and weighting in the pseudo 
cohort) which needs to be considered in the simulation of data under the null 
hypothesis. Furthermore, to allow variable follow-up between observations the timing 
of events (including clusters of events) in relation to baseline needs to be considered. 
With methods that address these obstacles the opportunity of adverse event data 
mining in pediatrics would be even more promising in the future.   
  
5.4.3 Best practices in pediatric pharmacoepidemiology 
To ensure usefulness of drug safety data from the observational setting and to facilitate 
comparison and aggregation of results from different studies robust design and 
statistical methods are key. In terms of design, sensible definitions of eligibility and 
exposure that are strictly applied throughout the cohort and study period (e.g. with 
sequential cohorts) are crucial. As described above (section 5.2.2), many types of 
common biases can be avoided and study results can be clearly interpreted by relying 
on these principles. Another vital design feature is active comparators, which can 
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mitigate information bias and confounding by indication. As discussed in section 5.2.3, 
the less restrictive prevalent new user designs are useful in pediatrics to maximize 
generalizability and efficiency and yet gain the benefits of confounding control from an 
active comparator design.  
Confounding control in pediatrics offers some particular opportunities. Low age and 
short disease and treatment history means that complete data on patients since disease 
onset or even since birth is available for a large proportion of patients in national 
registers. The possibility to characterize patients at the initiation of a drug based on 
their entire history, based on large sets of proxy factors, can potentially improve 
confounding adjustments and needs to be explored in the future.  
As described in section 5.2.5, confounding control can also be improved with flexible, 
data-adaptive PS modeling and with empirically identified potential confounders. Given 
the challenge of confounding by indication and the complexities of secondary data 
sources, applying data adaptive methods is as viable as traditional methods for 
covariate selection. In many cases, these approaches can be applied in parallel and 
evaluated based on their strengths and limitations. Further, doubly robust methods, 
such as targeted maximum likelihood estimation, where both the treatment and 
outcome are modeled to reduce bias and increase efficiency, are promising in pediatric 
pharmacoepidemiology where statistical precision can be low. However, the small 
sample properties of these methods need to be explored further.  
Finally, the as-treated analysis is often the most relevant analysis from a drug safety 
perspective, since a potential adverse effect can be diluted and not detected in an as-
initiated analysis. Nonetheless, as pointed out in section 5.2.6, this analysis can be 
susceptible to informative censoring. Methods for time-updated adjustment in an as-
treated analysis, e.g. IPC weighting, are generally underutilized and would add 








The overall aim of this thesis was to develop new, relevant, and pediatric-specific safety 
evidence for treatments in chronic inflammatory diseases. Based on data from 
Scandinavian national health care registers, we found that use of azathioprine was 
associated with a 6-fold increased risk of acute pancreatitis in pediatric IBD. When 
investigating the use of TNF-α inhibitors and the risk of serious infection, we found a 
two-fold increased risk in JIA patients, but no increased risk in patients with pediatric 
IBD. Through data mining we screened the registers for new signals of adverse events of 
TNF-α inhibitors in both pediatric IBD and JIA patients. We identified two signals; none 
of which were deemed relevant for further investigation. Finally, we investigated the 
differences between common designs in pharmacoepidemiology and provided guidance 
on key factors that need to be considered when choosing a comparator in an 
observational drug safety study.  
This thesis was driven by the need for relevant safety data when drugs are prescribed to 
children. Pediatric patients are vastly understudied when it comes to drug safety, both 
historically and today. The shortage of data applies to most pediatric indications and is 
by no means limited to chronic inflammatory diseases. Hopefully this work will inspire 







7 POPULAR SCIENCE SUMMARY 
There is a key question that physicians need to ask before prescribing drugs to children: 
Is this drug safe? Physicians rely on information from large trials where drugs are 
tested in controlled settings. Although the testing of drugs has progressed tremendously 
during the previous century and is highly regulated to protect patients, the information 
that comes from trials rarely applies to children. Consequently, when prescribing to 
children, physicians need to rely on what they know about risks to adults, which may 
not be relevant because children and adults often react differently to treatments. The 
overall aim of this thesis was to bridge this gap using data from Scandinavian clinical 
practice to investigate the safety of some drugs that are commonly used in children with 
chronic inflammatory diseases. Our data covered 5.3 million children in Denmark and 
Sweden; including 21,000 patients with these diseases. 
We did studies on specific safety concerns where we need more information, i.e. drugs 
that may potentially cause certain adverse events. First, we looked at azathioprine, 
which is a common drug that suppresses the body’s immune system, and if it increased 
the risk of acute pancreatitis in children with inflammatory bowel disease. Acute 
pancreatitis is the sudden and often painful inflammation of the pancreas. When looking 
at children in Denmark and Sweden who used azathioprine, we found that the drug 
increased the risk of acute pancreatitis by six times. Among the children who used 
azathioprine, 1.2% experienced this event in the first 90 days of starting the drug. 
Second, we studied modern and highly efficacious biologic treatments to see if they 
increased the risk of serious infections, defined as infections where the patient needs to 
be hospitalized. In two separate studies based on Danish patients, we found that the use 
of biologic treatments increased the risk of serious infection by two times in children 
with rheumatic disease; whereas it did not increase the risk in children with 
inflammatory bowel disease. 
We also did a study of biologic treatments in children, where we searched the data for 
any new signals of adverse events that were previously unknown, rather than looking at 
a particular adverse event. We searched among more than 1000 diagnoses and found 
increased risks in two of them, skin complications and adjustment disorders; neither of 
which were considered relevant for further investigation. 
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Finally, we addressed a critical methodological issue when studying safety of drugs 
based on data from clinical practice: the choice of comparator group, i.e. the patients 
that we compare to the treated patients. We relied on concepts from the world of 
clinical trials and concluded that multiple factors influence the selection of comparator 
group, e.g. if there are patients who use similar drugs that can be used as comparator, if 
the potential risk of the drug is expected to vary between patient groups, and the size of 
our patient sample. 
In summary, we investigated concerns related to the risks of certain drugs in children 
with chronic inflammatory diseases. We showed that information that can support 
physicians when prescribing to children can be derived from data from clinical practice 
in Scandinavia. Given the dearth of this type of data in children hopefully this work will 





8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
När läkare förskriver mediciner till barn behöver de ställa frågan: Är läkemedlet säkert? 
Läkare använder information från kliniska prövningar där mediciner testas på ett 
kontrollerat sätt och även om dessa är strikt reglerade för att skydda patienter gäller 
informationen från prövningar sällan barn. Det innebär att läkare som behandlar barn 
behöver förlita sig på riskinformation som är känd från vuxna, vilken inte nödvändigtvis 
är relevant då barn och vuxna reagerar olika på många mediciner. Syftet med den här 
avhandlingen var att utifrån data från klinisk praxis i Skandinavien undersöka risker 
med läkemedel som är vanliga hos barn med kroniska inflammatoriska sjukdomar. Våra 
data täckte 5.3 miljoner barn i Danmark och Sverige; varav 21,000 var patienter med 
dessa sjukdomar. 
Vi genomförde studier på specifika läkemedelsrisker; mediciner som eventuellt orsakar 
vissa biverkningar där vi behöver mer information. I en studie undersökte vi om 
användning av azatioprin, en vanlig medicin som hämmar immunförsvaret, ökar risken 
för akut pankreatit hos barn med inflammatorisk tarm. Akut pankreatit är en plötslig 
och ofta smärtsam inflammation av bukspottkörteln. När vi tittade på patienter i 
Danmark och Sverige fann vi att användning av azatioprin ökade risken för akut 
pankreatit med sex gånger. Bland barn som använde azatioprin fick 1,2% denna 
biverkning under de första 90 dagarna efter behandlingsstart. I de andra studierna 
undersökte vi om användningen av biologiska läkemedel, som tillhör senaste 
generationen av behandlingar och är mycket effektiva, ökade risken för allvarlig 
infektion (som kräver att patienten blir inlagd på sjukhus). I två separata studier tittade 
vi på danska patienter och fann att biologiska läkemedel ökade risken för allvarlig 
infektion med två gånger hos barn med reumatisk sjukdom; medan risken inte ökade 
hos barn med inflammatorisk tarm.  
Vi gjorde också en studie på biologiska läkemedel hos barn där vi sökte efter signaler på 
nya biverkningar som tidigare inte var kända. Vi sökte bland fler än 1000 diagnoser och 
hittade signaler på ökad risk i två av dem: hudsjukdomar och anpassningssvårigheter. 
Ingen av dessa ansågs relevant för en fördjupad undersökning. 
Slutligen så undersökte vi en kritisk fråga om metodval i studier av biverkningar utifrån 
data från kliniska praxis: valet av jämförelsegrupp. Vi använde koncept från 
utformningen av kliniska prövningar och drog slutsatsen att valet av jämförelsegrupp 
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beror på en rad faktorer, t ex om det finns patienter som använder liknande läkemedel 
som kan användas som jämförelsegrupp, om risken för biverkning tros variera mellan 
olika patientgrupper, och hur stort antal patienter som kan analyseras. 
Sammanfattningsvis undersökte vi risker för biverkningar av mediciner hos barn med 
kroniska inflammatoriska sjukdomar. Vi visade att information om risker som kan 
användas vid förskrivning av läkemedel till barn kan tas fram utifrån data från klinisk 
praxis i Skandinavien. På grund av den fortsatt stora bristen på denna typ av 
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